



Registration of a Charge

Company Name: **GW RESEARCH LIMITED**

Company Number: **03107561**



Received for filing in Electronic Format on the: **27/07/2021**

XA9LIENV

Details of Charge

Date of creation: **21/07/2021**

Charge code: **0310 7561 0002**

Persons entitled: **U.S. BANK NATIONAL ASSOCIATION AS COLLATERAL TRUSTEE**

Brief description: **UK PATENT REGISTRATION NUMBER GB2516335, UK PATENT REGISTRATION NUMBER GB2530001 AND THOSE ASSETS LISTED IN SCHEDULE 1 OF THE INSTRUMENT. FOR MORE DETAILS, PLEASE REFER TO THE INSTRUMENT.**

Contains fixed charge(s).

Contains negative pledge.

Authentication of Form

This form was authorised by: **a person with an interest in the registration of the charge.**

Authentication of Instrument

Certification statement: **I CERTIFY THAT, SAVE FOR MATERIAL REDACTED PURSUANT TO S. 859G OF THE COMPANIES ACT 2006, THE ELECTRONIC COPY INSTRUMENT DELIVERED AS PART OF THIS APPLICATION FOR REGISTRATION IS A CORRECT COPY OF THE ORIGINAL INSTRUMENT.**

Certified by: **CAHILL GORDON & REINDEL (UK) LLP**



CERTIFICATE OF THE REGISTRATION OF A CHARGE

Company number: 3107561

Charge code: 0310 7561 0002

The Registrar of Companies for England and Wales hereby certifies that a charge dated 21st July 2021 and created by GW RESEARCH LIMITED was delivered pursuant to Chapter A1 Part 25 of the Companies Act 2006 on 27th July 2021 .

Given at Companies House, Cardiff on 29th July 2021

The above information was communicated by electronic means and authenticated by the Registrar of Companies under section 1115 of the Companies Act 2006



Companies House



**THE OFFICIAL SEAL OF THE
REGISTRAR OF COMPANIES**

Supplement No. 1 to the Collateral Agreement

SUPPLEMENT NO. 1 (this “**Supplement**”), dated as of July 21, 2021 to the Collateral Agreement, dated as of May 5, 2021 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “**Collateral Agreement**”), among JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (“**Parent**”), Jazz Securities Designated Activity Company, each other Subsidiary Loan Party listed on the signature pages thereof and each other Subsidiary Loan Party that becomes a party thereto after the date thereof (together with Parent, the “**Pledgors**”) and U.S. BANK NATIONAL ASSOCIATION, as collateral trustee (together with its successors and assigns in such capacity, the “**Collateral Trustee**”) for the Senior Lien Secured Parties (as defined therein).

A. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Collateral Agreement.

B. The Pledgors have entered into the Collateral Agreement pursuant to the requirements set forth in the applicable Senior Lien Documents (as defined in the Collateral Agreement). Section 5.16 of the Collateral Agreement provides that additional Subsidiary Loan Parties may become Pledgors under the Collateral Agreement by execution and delivery of an instrument in the form of this Supplement. Each undersigned Subsidiary (collectively, the “**New Subsidiaries**”) is executing this Supplement in accordance with the requirements of the applicable Senior Lien Documents to become a Pledgor under the Collateral Agreement.

Accordingly, each New Subsidiary agrees as follows:

SECTION 1. In accordance with Section 5.16 of the Collateral Agreement, such New Subsidiary by its signature below becomes a Pledgor under the Collateral Agreement with the same force and effect as if originally named therein as a Pledgor and such New Subsidiary hereby (a) agrees to all the terms and provisions of the Collateral Agreement applicable to it as a Pledgor thereunder and (b) represents and warrants that the representations and warranties made by it as a Pledgor thereunder are true and correct in all material respects on and as of the date hereof. In furtherance of the foregoing, such New Subsidiary, as security for the payment and performance in full of its Senior Lien Obligations, does hereby create and grant to the Collateral Trustee, its successors and assigns, for the benefit of the Senior Lien Secured Parties, their successors and assigns, a security interest in and lien on all of such New Subsidiary’s right, title and interest in and to the Collateral (as defined in the Collateral Agreement) of such New Subsidiary; *provided that*, for the avoidance of doubt, the Collateral shall not include any Excluded Property. Each reference to a “Pledgor” in the Collateral Agreement shall be deemed to include such New Subsidiary. The Collateral Agreement is hereby incorporated herein by reference.

SECTION 2. Such New Subsidiary represents and warrants to the Collateral Trustee and the other Senior Lien Secured Parties that this Supplement has been duly authorized, executed and delivered by it and constitutes its legal, valid and binding obligation, enforceable against it in accordance with its terms, subject to (i) the effects of bankruptcy, insolvency, fraudulent conveyance or other similar laws affecting creditors’ rights generally, (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and (iii) implied covenants of good faith and fair dealing.

SECTION 3. This Supplement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Supplement shall become effective when the Collateral Trustee shall have received a counterpart of this Supplement that bears the signature of such New Subsidiary. Delivery of an executed signature page to this Supplement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed counterpart of this Supplement.

SECTION 4. Such New Subsidiary hereby represents and warrants that, as of the date hereof, (a) set forth on *Schedule I* attached hereto is a true and correct schedule of any and all of (and, with respect to any Pledged Stock issued by an issuer that is not a subsidiary of Parent, correctly sets forth, to the knowledge of such New Subsidiary) the percentage of the issued and outstanding units of each class of the Equity Interests of the issuers thereof represented by the Pledged Stock and includes (i) all Equity Interests pledged hereunder and (ii) all Pledged Debt pledged hereunder in an individual principal amount in excess of \$5,000,000 now owned by such New Subsidiary required to be pledged in order to satisfy the Collateral and Guarantee Requirement or delivered pursuant to Sections 2.2(a) and 2.2(b) of the Collateral Agreement, (b) set forth on *Schedule II* attached hereto is a list of any and all Intellectual Property now owned by such New Subsidiary consisting of Patents and Trademarks applied for or registered with the United States Patent and Trademark Office and Copyrights registered with the United States Copyright Office, (c) set forth on *Schedule III* attached hereto is a list of any and all Commercial Tort Claims of such New Subsidiary individually in excess of \$10,000,000 and (d) set forth under its signature hereto is the true and correct legal name of such New Subsidiary, its jurisdiction of organization and the location of its chief executive office. *Schedule III* hereto shall supplement Schedule IV to the Collateral Agreement. Attached hereto as *Schedule IV* is a Perfection Certificate with respect to each New Subsidiary.

SECTION 5. Except as expressly supplemented hereby, the Collateral Agreement shall remain in full force and effect.

SECTION 6. THIS SUPPLEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS SUPPLEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.

SECTION 7. In case any one or more of the provisions contained in this Supplement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and in the Collateral Agreement shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other jurisdiction). The parties hereto shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or unenforceable provisions.

SECTION 8. All communications and notices hereunder shall (except as otherwise expressly permitted by the Collateral Agreement) be in writing and given as provided in Section 5.1 of the Collateral Agreement.

SECTION 9. Such New Subsidiary agrees to reimburse the Collateral Trustee for its reasonable and documented out-of-pocket expenses in connection with this Supplement, including the reasonable and documented fees, other charges and disbursements of counsel for the Collateral Trustee.

[Signature Page Follows]

IN WITNESS WHEREOF, each New Subsidiary has duly executed this Supplement to the Collateral Agreement as of the day and year first above written.

GW PHARMACEUTICALS LIMITED

By: 

Name: Iain Ward
Title: Director

GW GLOBAL SERVICES (INTERNATIONAL) LIMITED

By: 

Name: Iain Ward
Title: Director

GW PHARMA LIMITED

By: 

Name: Iain Ward
Title: Director

GW RESEARCH LIMITED

By: 


Name: Iain Ward
Title: Director

GW UK SERVICES LIMITED

By: 

Name: Iain Ward
Title: Director

GREENWICH BIOSCIENCES, INC.



[Signature Page to Supplement No. 1 to Collateral Agreement]

Pledged Stock; Pledged Debt

A. Pledged Stock

Issuer	Record Owner	Certificate No.	Number and Class	Percentage of Equity Interest Owned	Percent Pledged
GW Pharmaceuticals Limited	Jazz Pharmaceuticals UK Holdings Limited (all but 2 shares) ¹ Jazz Pharmaceuticals plc (2 shares)	Uncertificated	378,535,932	100%	100%
GW Global Services (International) Limited	GW Pharmaceuticals Limited	Replacement No. 1	100	100%	100%
GW Pharma Limited	GW Pharmaceuticals Limited	Replacement No. 1	156,294,507	100%	100%
GW Research Limited	GW Pharmaceuticals Limited	Replacement No. 1	5,604,054	100%	100%
Greenwich Biosciences, Inc.	GW Pharmaceuticals Limited	Uncertificated	100	100%	100%
GW UK Services Limited	GW Pharma Limited	Replacement No. 1	2	100%	100%

B. Pledged Debt

Subordinated Intercompany Note dated as of May 5, 2021.

¹ Note that 97% of the shares of GW Pharmaceuticals Limited will be held directly by the DR Nominee and Jazz Pharmaceuticals UK Holdings Limited will be issued a depositary receipt in respect of the same.

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Intellectual Property

A. U.S. Federally Issued or Applied for Patents

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Albania
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Albania
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Albania
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Albania
GW Research Limited	CBD-C4 first medical use	PCT/GB2019/053284			ARIPO
GW Pharma Limited	CBDV EPILEPSY	201290975	036044	17/Sep/2020	Armenia
GW Pharma Limited	Hot gas extraction method	2002255150	2002255150	22/Jan/2009	Australia
GW Pharma Limited	Supercritical CO2 extraction	2003253002	2003253002	11/Mar/2010	Australia
GW Pharma Limited	THCV in treatment of appetite disorders	2005305675	2005305675	25/Mar/2013	Australia
GW Pharma Limited	Chemotherapeutic Agents	2009254935	2009254935	02/Jul/2015	Australia
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	2018217273	2018217273	25/Jun/2020	Australia
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	2012260611			Australia
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	2013201809	2013201809	06/Aug/2015	Australia
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	2003253005	2003253005	05/Nov/2013	Australia
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	PCT/GB2015/053028			Australia
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	2008346285	2008346285	16/Jul/2015	Australia
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	2009254936	2009254936	02/Jul/2015	Australia
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	2010267775	2010267775	19/Jan/2017	Australia
GW Pharma Limited	CBDV EPILEPSY	2011234225	2011234225	16/Feb/2017	Australia
GW Pharma Limited	CBD / SAED'S combination	2012204800	2012204800	07/Sep/2017	Australia
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	2012314129	2012314129	18/Dec/2017	Australia
GW Research Limited	Pharmaceutical compositions containing cannabinoids	2002231970	2002231970	29/Nov/2007	Australia
GW Research Limited	Pharmaceutical formulations (Sativex product)	2003253005	2003253005	03/Jul/2009	Australia
GW Research Limited	Pharmaceutical formulations (Sativex product)	2009202434	2009202434	13/Dec/2012	Australia
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	2005251505	2005251505	14/Jul/2011	Australia

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	2020220135			Australia
GW Research Limited	Absence Seizures	2020217417			Australia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	2015332208			Australia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	2021201510			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2015332212			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	2015332220	2015332220	14/Jan/2021	Australia
GW Research Limited	Dravet trilogy	2016278088			Australia
GW Research Limited	CBDA for use in epilepsy	2016305545			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	2016320505			Australia
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	2017251607			Australia
GW Research Limited	CBDV patent in Autism	2017251604			Australia
GW Research Limited	Gel Formulation	2017287868			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	2017374777			Australia
GW Research Limited	CBD for use in TSC tumours	2018288021			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2018341091			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2018366443			Australia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2018374550			Australia
GW Research Limited	Gel Formulation Packaging	2019205117			Australia
GW Research Limited	Modified Release Formulation	2019205118			Australia
GW Research Limited	THC/CBD Gel Formulation	2019205119			Australia
GW Research Limited	CBD STP epilepsy	2019211224			Australia
GW Research Limited	Project Nano CBD	2019259230			Australia
GW Research Limited	CBD-C4 first medical use	2019382961			Australia
GW Research Limited	GRIN2A epilepsy	2019387553			Australia
GW Pharma Limited	Supercritical CO2 extraction	1536810	568281	01/Aug/2012	Austria
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Austria
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	619300	03/Jul/2013	Austria
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	929618	20/Sep/2017	Austria
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Austria

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	824375	31/Aug/2016	Austria
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	774321	10/Feb/2016	Austria
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	864972	01/Feb/2017	Austria
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	SZ 25/2012	SZ 25/2012	08/Apr/2013	Austria
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	EP2768493	31/Jul/2019	Austria
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	757545	28/Oct/2015	Austria
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	EP2609928	17/Jul/2019	Austria
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	811710	13/Jul/2016	Austria
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	992121	25/Apr/2018	Austria
GW Pharma Limited	Absence Seizures	15732887.3	992122	25/Apr/2018	Austria
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	EP3095452	17/Jul/2019	Austria
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	655834	12/Mar/2014	Austria
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	533472	14/Feb/2012	Austria
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	EP1765314	01/May/2019	Austria
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	867510	15/Feb/2017	Austria
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	1031658	22/Aug/2018	Austria
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Austria
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Austria
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Austria
GW Pharma Limited	CBDV EPILEPSY	201290975	036044	17/Sep/2020	Azerbaijan
GW Pharma Limited	CBDV EPILEPSY	PCT/GB2011/050649	036044	17/Sep/2020	Belarus
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Belgium
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	EP2037902	03/Jul/2013	Belgium
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Belgium
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	EP2275097	07/Aug/2019	Belgium
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	EP2311475	31/Aug/2016	Belgium
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Belgium
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	EP2709604	01/Feb/2017	Belgium

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	EP2768493	31/Jul/2019	Belgium
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Belgium
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	EP2609928	17/Jul/2019	Belgium
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	2013C/010	2013C/010	22/Jul/2015	Belgium
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Belgium
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Belgium
GW Pharma Limited	Absence Seizures	15732887.3	EP3157512	25/Apr/2018	Belgium
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	EP3095452	17/Jul/2019	Belgium
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	EP2448637	12/Mar/2014	Belgium
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Belgium
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	EP1765314	01/May/2019	Belgium
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Belgium
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	EP2314284	15/Feb/2017	Belgium
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Belgium
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Belgium
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Belgium
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Belgium
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	PI0913384.4			Brazil
GW Pharma Limited	Chemotherapeutic Agents	PI0911384.3			Brazil
GW Pharma Limited	CBD / SAED'S combination	1120130171545			Brazil
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	1120140075190			Brazil
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	1120120000764			Brazil
GW Research Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	BR1120140304068			Brazil
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	BR1120160295064			Brazil
GW Research Limited	Absence Seizures	BR1120160294980			Brazil
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	BR 112017007767.1			Brazil

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	BR 1120170077779			Brazil
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	BR 112017007774			Brazil
GW Research Limited	Dravet trilogy	BR112017027166 4			Brazil
GW Research Limited	CBDA for use in epilepsy	BR 1120180026026			Brazil
GW Research Limited	Gel Formulation	BR 11 2018 076601 1			Brazil
GW Research Limited	CBD for use in TSC tumours	BR 11 2019 027454 5			Brazil
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	BR 11 2020 006105 0			Brazil
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	BR 11 2020 009508 7			Brazil
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	BR112020010161 3			Brazil
GW Research Limited	Gel Formulation Packaging	BR 11 2020 013433 3			Brazil
GW Research Limited	Modified Release Formulation	BR 11 2020 013446 5			Brazil
GW Research Limited	THC/CBD Gel Formulation	BR 11 2020 013450 3			Brazil
GW Research Limited	CBD STP epilepsy	BR 11 2020 015018 5			Brazil
GW Research Limited	Project Nano CBD	BR 112020021884 7			Brazil
GW Research Limited	CBD-C4 first medical use	BR 11 2021 009815 1			Brazil
GW Research Limited	GRIN2A epilepsy	PCT/GB2019/053372			Brazil
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Aug/2012	Bulgaria
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Bulgaria
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Bulgaria
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Bulgaria
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Bulgaria
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Bulgaria
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Bulgaria
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Bulgaria
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Bulgaria
GW Pharma Limited	Hot gas extraction method	2,446,195	2,446,195	22/Jul/2008	Canada
GW Pharma Limited	Supercritical CO2 extraction	2,455,129	2,455,129	22/Oct/2013	Canada
GW Pharma Limited	Supercritical CO2 extraction	2,994,322			Canada
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	2,499,492	2,499,492	12/Jul/2011	Canada
GW Pharma Limited	CBD in inhibition of tumour cell migration	2,582,289	2,582,289	14/Oct/2014	Canada
GW Pharma Limited	THCV in treatment of appetite disorders	2,586,358	2,586,358	24/Nov/2015	Canada
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	2,655,094	2,655,094	30/Sep/2014	Canada
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	2,656,698	2,656,698	13/Oct/2015	Canada
GW Pharma Limited	Chemotherapeutic Agents	2,726,257	2,726,257	13/Sep/2016	Canada

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	2833099	2,833,099	03/Nov/2020	Canada
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	2,708,921	2,708,921	20/Mar/2018	Canada
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	2,726,258	2,726,258	12/Sep/2017	Canada
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	2,766,082	2,766,082	11/Jun/2019	Canada
GW Pharma Limited	CBDV EPILEPSY	2,794,620	2,794,620	13/Mar/2018	Canada
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	3,040,410			Canada
GW Pharma Limited	CBD / SAED'S combination	2,822,907	2,822,907	18/Aug/2020	Canada
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	2,845,677	2,845,677	18/Aug/2020	Canada
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	3,040,410			Canada
GW Research Limited	Pharmaceutical compositions containing cannabinoids	2,438,097	2,438,097	25/Apr/2006	Canada
GW Research Limited	Pharmaceutical compositions containing cannabinoids	2,533,400	2,533,400	03/Jan/2017	Canada
GW Research Limited	Pharmaceutical formulations (Sativex product)	2,454,644	2,454,644	16/Sep/2014	Canada
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	2,568,997	2,568,997	04/Dec/2012	Canada
GW Research Limited	Cannabinoid extracts as neuroprotectants	2,636,634	2,636,634	11/Jul/2017	Canada
GW Research Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	2874968	2,874,968	18/Feb/2020	Canada
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	2,952,994			Canada
GW Research Limited	Absence Seizures	2,952,858			Canada
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	2,963,202			Canada
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2,963,208			Canada
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	2,963,211			Canada
GW Research Limited	Dravet trilogy	2,989,779			Canada
GW Research Limited	CBDA for use in epilepsy	2,992,802			Canada
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	2,995,927			Canada
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	3,020,528			Canada
GW Research Limited	CBDV patent in Autism	3,020,500			Canada
GW Research Limited	Gel Formulation	3,028,580			Canada

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	3,046,442			Canada
GW Research Limited	CBD for use in TSC tumours	3065449			Canada
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	3,076,995			Canada
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	3,082,433			Canada
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	3,083,144			Canada
GW Research Limited	Gel Formulation Packaging	3,087,122			Canada
GW Research Limited	Modified Release Formulation	3,087,125			Canada
GW Research Limited	THC/CBD Gel Formulation	3,087,802			Canada
GW Research Limited	CBD STP epilepsy	3,089,404			Canada
GW Research Limited	Project Nano CBD	3,097,665			Canada
GW Research Limited	CBD-C4 first medical use	TBC			Canada
GW Research Limited	GRIN2A epilepsy	PCT/GB2019/053372			Canada
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	03902	2008-003902	10/Jul/2017	Chile
GW Pharma Limited	Supercritical CO2 extraction	03824211.7	ZL03824211.7	08/Dec/2010	China
GW Pharma Limited	THCV in treatment of appetite disorders	200580039064.1	200580039064.1	17/Aug/2016	China
GW Pharma Limited	Chemotherapeutic Agents	200980120573.5	1663502	13/May/2015	China
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	200880125822.5	ZL200880125822.5	17/Aug/2016	China
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	200980120759.0	ZL200980120759.0	07/Oct/2015	China
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	201610808754.9			China
GW Pharma Limited	CBDV EPILEPSY	201180026947.4	ZL201180026947.4	16/Mar/2016	China
GW Pharma Limited	CBD / SAED'S combination	201710873483X			China
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOID CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	CN2018101490434			China
GW Research Limited	Pharmaceutical compositions containing cannabinoids	02808220.6	ZL02808220.6	26/Feb/2014	China
GW Research Limited	Pharmaceutical formulations (Sativex product)	03824097.1	ZL03824097.1	24/Mar/2010	China
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	200580018647.6	ZL200580018647.6	25/May/2011	China
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2018800638269			China
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2018800801754			China
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2018800761418			China
GW Research Limited	Gel Formulation Packaging	2019800150283			China

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	Modified Release Formulation	201980015013.7			China
GW Research Limited	THC/CBD Gel Formulation	201980014990.5			China
GW Research Limited	CBD STP epilepsy	201980010033.5			China
GW Research Limited	Project Nano CBD	2019800432608			China
GW Research Limited	CBD-C4 first medical use	TBC			China
GW Research Limited	GRIN2A epilepsy	PCT/GB2019/053372			China
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Croatia
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Croatia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	P20201325T	27/May/2020	Croatia
GW Research Limited	USE OF CANNABINOID IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	P20201230T	29/Jul/2020	Croatia
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Croatia
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Cyprus
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Cyprus
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Cyprus
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Cyprus
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Cyprus
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Cyprus
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Cyprus
GW Research Limited	USE OF CANNABINOID IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Cyprus
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Cyprus
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	PV2003-2458	306277	29/Sep/2016	Czech Republic
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Czech Republic
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Czech Republic
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Czech Republic
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Czech Republic
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	EP2311475	31/Aug/2016	Czech Republic
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10180523.2	EP2314284	15/Feb/2017	Czech Republic
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Czech Republic
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	SPC/CZ 2012-219	1542657/219	16/Apr/2011	Czech Republic
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Czech Republic
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Czech Republic
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Czech Republic

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Czech Republic
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Czech Republic
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Czech Republic
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Czech Republic
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Denmark
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	Denmark
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Denmark
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Denmark
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Denmark
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Denmark
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	CA 2012 00016	CA 2012 00016	30/Jul/2012	Denmark
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Denmark
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Denmark
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Denmark
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Denmark
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Denmark
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Denmark
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Denmark
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Denmark
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Denmark
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Denmark
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Estonia
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Estonia
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Estonia
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Estonia
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Estonia
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Estonia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Estonia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Estonia
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Estonia

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	201490711	029697	31/May/2018	Eurasia
GW Research Limited	Project Nano CBD	202092582			Eurasia
GW Research Limited	CBD-C4 first medical use	PCT/GB2019/053284			Eurasia
GW Pharma Limited	Sublingual application of cannabis (Pharmasol)	01910026.2	1280515	14/Feb/2007	Europe
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	02712063.3	BP1361864	04/Dec/2013	Europe
GW Pharma Limited	Hot gas extraction method	02724458.1	1385595	02/May/2012	Europe
GW Pharma Limited	CBDa in treatment of motion sickness	03734779.6	BP1482917	08/May/2019	Europe
GW Pharma Limited	CBDa in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Europe
GW Pharma Limited	ADS patient diary	03708317.7	1478420	09/Sep/2009	Europe
GW Pharma Limited	ADS patient diary	09169652.6	BP2123318	13/Jan/2016	Europe
GW Pharma Limited	Supercritical CO2 extraction	03787897.2	1536810	01/Aug/2012	Europe
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Europe
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Europe
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Europe
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	1542984	02/Dec/2009	Europe
GW Pharma Limited	CBC in the treatment of depression	04743065.7	BP1644349	09/Apr/2014	Europe
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Europe
GW Pharma Limited	CBD in inhibition of tumour cell migration	05788521.2	1802274	17/Sep/2008	Europe
GW Pharma Limited	THCV in treatment of appetite disorders	05803521.3	BP1811983	07/Oct/2020	Europe
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Europe
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Europe
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	07733222.9	2037901	08/Jan/2014	Europe
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	Europe
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	EP08737019.3	BP2146731	16/Jan/2019	Europe
GW Pharma Limited	Zero cannabinoid plant	08750728.1	BP2162144	28/Apr/2021	Europe
GW Pharma Limited	Zero cannabinoid plant	21170550.4			Europe
GW Pharma Limited	New use for cannabinoid-containing plant extracts	08762489.6	2182940	12/Mar/2014	Europe
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Europe
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Europe
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Europe
GW Pharma Limited	Chemotherapeutic Agents	16201983.0			Europe
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	11709175.1	BP2544682	10/Feb/2016	Europe
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Europe

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	12731151.2	BP2726069	01/May/2019	Europe
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Europe
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Europe
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	15185536.8	BP3028697	26/Dec/2018	Europe
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	12794753.9	BP2782563	25/Apr/2018	Europe
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	13729798.2	BP2858633	13/Jul/2016	Europe
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	16777760.6	BP3355873	21/Oct/2020	Europe
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Europe
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	20201377.7			Europe
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	BP2448637	12/Mar/2014	Europe
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	20175934.7			Europe
GW Pharma Limited	CBDV EPILEPSY	20194696.9			Europe
GW Pharma Limited	CBD / SAED'S combination	12700294.7	BP2661263	14/Apr/2021	Europe
GW Pharma Limited	CBD / SAED'S combination	20193228.2			Europe
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	20192084.0			Europe
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	14717843.8	BP2986289	31/Oct/2018	Europe
GW Research Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	14732613.6	BP3010497	10/Apr/2019	Europe
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14732614.4	BP3010498	04/Mar/2020	Europe
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Europe
GW Research Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Europe
GW Research Limited	ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER	15733502.7	BP3160455	12/May/2021	Europe

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER	21173064.3			Europe
GW Research Limited	7-OH-CBD DIABETES	15733513.4	EP3160456	25/Sep/2019	Europe
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	15733514.2	EP3160457	20/Nov/2019	Europe
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	19204387.5			Europe
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784112.3			Europe
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	15784113.1	EP3206680	21/Apr/2021	Europe
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	21166413.1			Europe
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP20182071.9			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15784121.4	EP3206681	10/Apr/2019	Europe
GW Research Limited	Dravet trilogy	16731281.8			Europe
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Europe
GW Research Limited	CBDA for use in epilepsy	20182674.0			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16766051.3	EP3346999	19/Jun/2019	Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	17715974.6			Europe
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	17718582.4			Europe
GW Research Limited	CBDV patent in Autism	17718580.8			Europe
GW Research Limited	Parenteral Formulations	EP17736733.1			Europe
GW Research Limited	Oral Cannabinoid Formulations (Low Ethanol)	EP17737351.1			Europe
GW Research Limited	Gel Formulation	EP17737028.5			Europe
GW Research Limited	MULTIPLE MYELOMA	EP17748905.1			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	17817833.1			Europe
GW Research Limited	Oral Aqueous Solution	18706562.8			Europe

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	LEUKAEMIA	18706846.5			Europe
GW Research Limited	CBD for use in TSC tumours	18737374.1			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER	18742590.5			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	18782178.0			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	18808075.8			Europe
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	18815319.1			Europe
GW Research Limited	Gel Formulation Packaging	19700426.0			Europe
GW Research Limited	Modified Release Formulation	19700427.8			Europe
GW Research Limited	THC/CBD Gel Formulation	19700428.6			Europe
GW Research Limited	CBD STP epilepsy	19702670.1			Europe
GW Research Limited	Project Nano CBD	EP19721363.0			Europe
GW Research Limited	CBD-C4 first medical use	19809598.6			Europe
GW Research Limited	GRIN2A epilepsy	19816424.6			Europe
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Finland
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Finland
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Finland
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Finland
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Finland
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Finland
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Finland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Finland
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Finland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Finland
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	C20180042			Finland
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Finland
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Finland
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Finland
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Finland
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Finland
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Finland
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Finland

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP1578411.5	BP3206716	29/Jul/2020	Finland
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Finland
GW Pharma Limited	Hot gas extraction method	1385595	1385595	30/Jul/2012	France
GW Pharma Limited	ADS patient diary	03708317.7	1478420	09/Sep/2009	France
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	08/Nov/2012	France
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	1542657	1542657	10/Feb/2012	France
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	1542984	03/Feb/2010	France
GW Pharma Limited	CBDA in treatment of motion sickness	03734779.6	BP1482917	08/May/2019	France
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	France
GW Pharma Limited	CBC in the treatment of depression	04743065.7	1644349	09/Apr/2014	France
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	France
GW Pharma Limited	THCV in treatment of appetite disorders	05803521.3	BP1811983	07/Oct/2020	France
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	France
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	07733222.9	2037901	08/Jan/2014	France
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	France
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	France
GW Pharma Limited	ADS patient diary	09169652.6	BP2123318	13/Jan/2016	France
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	EP08737019.3	BP2146731	16/Jan/2019	France
GW Pharma Limited	New use for cannabinoid-containing plant extracts	08762489.6	2182940	12/Mar/2014	France
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	France
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	France
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	France
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	France
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	France
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	France
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	12731151.2	BP2726069	01/May/2019	France
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	France
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	France
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	12794753.9	BP2782563	25/Apr/2018	France
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	France
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	France
GW Pharma Limited	Supplementary Protection Certificate	1542657	1542657	08/Aug/2014	France

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	France
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	France
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	15185536.8	BP3028697	26/Dec/2018	France
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	France
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	16777760.6	BP3355873	21/Oct/2020	France
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	France
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	France
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	14717843.8	BP2986289	31/Oct/2018	France
GW Research Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	14732613.6	BP3010497	10/Apr/2019	France
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14732614.4	BP3010498	04/Mar/2020	France
GW Research Limited	7-OH-CBD DIABETES	15733513.4	BP3160456	25/Sep/2019	France
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	15733514.2	BP3160457	20/Nov/2019	France
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	France
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	France
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15784121.4	BP3206681	10/Apr/2019	France
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	France
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16766051.3	BP3346999	19/Jun/2019	France
GW Pharma Limited	Hot gas extraction method	1385595	60242806	27/Jul/2012	Germany
GW Pharma Limited	ADS patient diary	03708317.7	60329169	09/Sep/2009	Germany
GW Pharma Limited	Supercritical CO2 extraction	10337458.2	103 37 458.2	14/Oct/2010	Germany
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	60330363	02/Dec/2009	Germany
GW Pharma Limited	CBDA in treatment of motion sickness	03734779.6	DE60351999.7	08/May/2019	Germany
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP1802274	602005009852	17/Sep/2008	Germany
GW Pharma Limited	CBC in the treatment of depression	04743065.7	602004044789	09/Apr/2014	Germany
GW Pharma Limited	THCV in treatment of appetite disorders	05803521.3	BP1811983	07/Oct/2020	Germany
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	07733222.9	602007034652	08/Jan/2014	Germany

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	602007031391	03/Jul/2013	Germany
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	602009048453	20/Sep/2017	Germany
GW Pharma Limited	ADS patient diary	09169652.6	60348469	13/Jan/2016	Germany
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	EP08737019.3	602008058773	16/Jan/2019	Germany
GW Pharma Limited	New use for cannabinoid-containing plant extracts	08762489.6	602008030842	12/Mar/2014	Germany
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	EP2275097	07/Aug/2019	Germany
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	60349355	31/Aug/2016	Germany
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	602011023212	10/Feb/2016	Germany
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	12 2012 000 032.2	DB 12 2012 000 032.2	24/Jul/2017	Germany
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	602012028260	01/Feb/2017	Germany
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	12731151.2	EP2726069	01/May/2019	Germany
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	EP2768493	31/Jul/2019	Germany
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	602012012034	28/Oct/2015	Germany
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	12794753.9	602012045683	25/Apr/2018	Germany
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	EP2609928	17/Jul/2019	Germany
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	602013009393	13/Jul/2016	Germany
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	602015010464	25/Apr/2018	Germany
GW Pharma Limited	Absence Seizures	15732887.3	602015010466	25/Apr/2018	Germany
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	15185536.8	EP3028697	26/Dec/2018	Germany
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	EP3095452	17/Jul/2019	Germany
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	60 2016 046 314.8	EP3355873	21/Oct/2020	Germany
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	602010014230	12/Mar/2014	Germany
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	602008044365	18/May/2016	Germany
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	60339152	13/Feb/2012	Germany
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	DE60200505571 4.8	01/May/2019	Germany

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Germany
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	60349905	15/Feb/2017	Germany
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	602007055900	22/Aug/2018	Germany
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	14717843.8	602014035073	31/Oct/2018	Germany
GW Research Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	14732613.6	EP3010497	10/Apr/2019	Germany
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14732614.4	EP3010498	04/Mar/2020	Germany
GW Research Limited	7-OH-CBD DIABETES	15733513.4	EP3160456	25/Sep/2019	Germany
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	15733514.2	EP3160457	20/Nov/2019	Germany
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Germany
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Germany
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15784121.4	EP3206681	10/Apr/2019	Germany
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Germany
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16766051.3	EP3346999	19/Jun/2019	Germany
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Greece
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Greece
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Greece
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Greece
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Greece
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Greece
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Greece
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Greece
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Greece
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	GC 2012-22834			Gulf Cooperation
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	GC2015-30192			Gulf Cooperation
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GC2015-30191			Gulf Cooperation
GW Pharma Limited	Use of One or More Cannabinoids in the Treatment of Epilepsy	GC 2010-16200	GC0005382	13/Apr/2017	Gulf Cooperation
GW Pharma Limited	CBDV EPILEPSY	GC 2011-18077			Gulf Cooperation

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	GC2012-22307			Gulf Cooperation
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX	2020/39667			Gulf Cooperation
GW Research Limited	CBD in epileptic spasms	2020/39811			Gulf Cooperation
GW Research Limited	Microparticulate formulations	2020/39850			Gulf Cooperation
GW Research Limited	CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF	2020/40122			Gulf Cooperation
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	2020/40191			Gulf Cooperation
GW Research Limited	(-)-cis-THC First Medical Use	2020/40720			Gulf Cooperation
GW Research Limited	(+)-cis-THC First Medical Use	2020/40719			Gulf Cooperation
GW Research Limited	(+)-trans-THC First Medical Use	2020/40718			Gulf Cooperation
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020/40917			Gulf Cooperation
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020/40918			Gulf Cooperation
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020/40927			Gulf Cooperation
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020/40928			Gulf Cooperation
GW Research Limited	ORAL CANNABINOID FORMULATIONS	2020/41197			Gulf Cooperation
GW Pharma Limited	Hot gas extraction method	04105745.3	1062901B	30/Nov/2012	Hong Kong
GW Pharma Limited	Supercritical CO2 extraction	05110252.7	HK1076249	26/Apr/2013	Hong Kong
GW Pharma Limited	CBC in the treatment of depression	06106628.1	HK1084670	19/Sep/2014	Hong Kong
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	10106725.7	1139877B	31/Jan/2020	Hong Kong
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13114250.1	HK1186416B	04/Sep/2020	Hong Kong
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	14111255.1	1197806B	15/May/2020	Hong Kong
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	11102763.8	1148672B	10/Nov/2017	Hong Kong
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	12105434.9	HK1164766B	30/Jan/2015	Hong Kong
GW Pharma Limited	Use of phytocannabinoid cannabidiol (CBD)	14100698.9			Hong Kong
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	62021028470.4			Hong Kong
GW Research Limited	Pharmaceutical compositions containing cannabinoids	03108883.0	HK1056509	17/Apr/2014	Hong Kong
GW Research Limited	Cannabinoid extracts as neuroprotectants	111113495.0	1158956B	04/Oct/2019	Hong Kong
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	18101164.8	1241723B	23/Apr/2021	Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	18101307.6			Hong Kong

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	Dravet trilogy	18112785.4			Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	HK19126535.4			Hong Kong
GW Research Limited	Gel Formulation	19131875.7			Hong Kong
GW Research Limited	Parenteral Formulations	19131877.3			Hong Kong
GW Research Limited	Oral Cannabinoid Formulations (Low Ethanol)	19131879.9			Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	62020004785.5			Hong Kong
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	42020018138.6			Hong Kong
GW Research Limited	CBD for use in TSC tumours	62020018338.7			Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	62020022136.9			Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	62021026961.4			Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	62021027906.8			Hong Kong
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	42021029621.6			Hong Kong
GW Research Limited	Gel Formulation Packaging	62021029619.5			Hong Kong
GW Research Limited	Modified Release Formulation	62021029618.7			Hong Kong
GW Research Limited	THC/CBD Gel Formulation	62021029617.9			Hong Kong
GW Research Limited	CBD STP epilepsy	62021029645.0			Hong Kong
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	P0303182	227.452	16/May/2011	Hungary
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Hungary
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Hungary
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Hungary
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Hungary
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Hungary
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Hungary
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Hungary
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Hungary
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Hungary
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Hungary
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Hungary
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Hungary

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Hungary
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Hungary
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	EP1765314	01/May/2019	Iceland
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Iceland
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Iceland
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Iceland
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Iceland
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Iceland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Iceland
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Iceland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Iceland
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Iceland
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Iceland
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Iceland
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Iceland
GW Pharma Limited	Supercritical CO2 extraction	562/DELNP/2005	242112	11/Aug/2010	India
GW Pharma Limited	Supercritical CO2 extraction	3362/DELNP/2007	251922	17/Apr/2012	India
GW Pharma Limited	THCV in treatment of appetite disorders	4431/DELNP/2007	264549	05/Jun/2015	India
GW Pharma Limited	Chemotherapeutic Agents	8136/DELNP/2010	292146	25/Jun/2018	India
GW Research Limited	Pharmaceutical formulations (Sativex product)	555/DELNP/2005	243249	30/Sep/2010	India
GW Research Limited	Pharmaceutical formulations (Sativex product)	4714/DELNP/2007	278673	28/Dec/2016	India
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	W00201002655			Indonesia
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	W00201100018	IDP000046588	20/Jun/2017	Indonesia
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	P00201907656			Indonesia
GW Pharma Limited	CBDV EPILEPSY	W00201204404	IDP000040364	18/Jun/2016	Indonesia
GW Pharma Limited	CBD / SAED'S combination	W00201303537	69849 - CHBCK?	15/Jul/2020	Indonesia
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	P00201402203	IDP000047952	29/Sep/2017	Indonesia
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	PCT/GB2012/051540			International

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	PCT/GB2012/052869			International
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	PCT/GB2012/052886			International
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	PCT/GB2013/051519			International
GW Pharma Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	PCT/GB2014/051159			International
GW Pharma Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	PCT/GB2014/051889			International
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	PCT/GB2015/051775			International
GW Pharma Limited	Absence Seizures	PCT/GB2015/051776			International
GW Pharma Limited	ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER	PCT/GB2015/051876			International
GW Pharma Limited	7-OH-CBD DIABETES	PCT/GB2015/051893			International
GW Pharma Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	PCT/GB2015/051894			International
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	PCT/GB2015/053029			International
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	PCT/GB2015/053030			International
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	PCT/GB2015/053024			International
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	PCT/GB2015/053028			International
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	PCT/GB2015/053044			International
GW Pharma Limited	CBDA for use in epilepsy	PCT/GB2016/052340			International
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	PCT/GB2016/052778			International
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	PCT/GB2016/053027			International
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	PCT/GB2010/051066			International
GW Pharma Limited	CBDV EPILEPSY	PCT/GB2011/050649			International
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	PCT/GB2012/052284			International
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	PCT/GB2012/052565			International

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	PCT/GB2012/051129			International
GW Pharma Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	PCT/GB2014/051888			International
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	PCT/GB2011/050487			International
GW Research Limited	Dravet trilogy	PCT/GB2016/051792			International
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	PCT/GB2017/050868			International
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	PCT/GB2017/051010			International
GW Research Limited	CBDV patent in Autism	PCT/GB2017/051007			International
GW Research Limited	Parenteral Formulations	PCT/GB2017/051913			International
GW Research Limited	Oral Cannabinoid Formulations (Low Ethanol)	PCT/GB2017/051914			International
GW Research Limited	Gel Formulation	PCT/GB2017/051943			International
GW Research Limited	MULTIPLE MYELOMA	PCT/GB2017/052229			International
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	PCT/GB2017/053735			International
GW Research Limited	Oral Aqueous Solution	PCT/GB2018/050404			International
GW Research Limited	LEUKAEMIA	PCT/GB2018/050421			International
GW Research Limited	CBD for use in TSC tumours	PCT/GB2018/051733			International
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER	PCT/GB2018/051954			International
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	PCT/GB2018/052805			International
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	PCT/GB2018/053315			International
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	PCT/GB2018/053483			International
GW Research Limited	Gel Formulation Packaging	PCT/GB2019/050007			International
GW Research Limited	Modified Release Formulation	PCT/GB2019/050008			International
GW Research Limited	THC/CBD Gel Formulation	PCT/GB2019/050009			International
GW Research Limited	CBD STP epilepsy	PCT/GB2019/050174			International
GW Research Limited	Project Nano CBD	PCT/GB2019/051173			International
GW Research Limited	CBD-C4 first medical use	PCT/GB2019/053284			International
GW Research Limited	GRIN2A epilepsy	PCT/GB2019/053372			International
GW Research Limited	CBD COMORBIDITIES	PCT/GB2020/050090			International
GW Research Limited	CBD EIFMS	PCT/GB2020/050383			International
GW Research Limited	CBD plus antibiotic	PCT/GB2020/050508			International
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX	PCT/GB2020/051080			International

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	CBD in epileptic spasms	PCT/GB2020/051185			International
GW Research Limited	Microparticulate formulations	PCT/GB2020/051290			International
GW Research Limited	CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF	PCT/GB2020/051723			International
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	PCT/GB2020/051803			International
GW Research Limited	THCV in PD dyskinesia	PCT/GB2020/052039			International
GW Research Limited	(-)-cis-THC First Medical Use	PCT/GB2020/052678			International
GW Research Limited	(+)-cis-THC First Medical Use	PCT/GB2020/052679			International
GW Research Limited	(+)-trans-THC First Medical Use	PCT/GB2020/052680			International
GW Research Limited	CBDV nano	PCT/GB2020/052694			International
GW Research Limited	CBD use in Fragile X syndrome	PCT/GB2020/052696			International
GW Research Limited	CBD use in temporal lobe epilepsy	PCT/GB2020/052697			International
GW Research Limited	CBD use in absence epilepsy	PCT/GB2020/052698			International
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	PCT/GB2020/052938			International
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	PCT/GB2020/052936			International
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	PCT/GB2020/052942			International
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	PCT/GB2020/052944			International
GW Research Limited	ORAL CANNABINOID FORMULATIONS	PCT/GB2020/053282			International
GW Research Limited	EPDX DDI Study	PCT/GB2021/050509			International
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Ireland
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	EP1802274	17/Sep/2008	Ireland
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	Ireland
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Ireland
GW Pharma Limited	COMPOSITIONS COMPRISING CANNABINOIDS FOR TREATMENT OF NAUSEA, VOMITING, EMESIS, MOTION SICKNESS OR LIKE CONDITIONS	10180470.6	EP2275097	07/Aug/2019	Ireland
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	EP2311475	31/Aug/2016	Ireland
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	EP2544682	10/Feb/2016	Ireland
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	EP2709604	01/Feb/2017	Ireland
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	EP2768493	31/Jul/2019	Ireland
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Ireland
GW Pharma Limited	Use of cannabinoids in combination with Aripiprazole	13152600.6	EP2609928	17/Jul/2019	Ireland
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Ireland

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	1542657	2014/049	17/Oct/2016	Ireland
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Ireland
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Ireland
GW Pharma Limited	USE OF CANNABIDIOL IN COMBINATION WITH ARIPIRAZOLE	16167562.4	BP3095452	17/Jul/2019	Ireland
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Ireland
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Ireland
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Ireland
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Ireland
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Ireland
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Ireland
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Ireland
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	BP15784111.5	BP3206716	29/Jul/2020	Ireland
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Ireland
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	157130	157130	01/Feb/2011	Israel
GW Pharma Limited	Hot gas extraction method	158709	158709	01/Feb/2008	Israel
GW Pharma Limited	THCV in treatment of appetite disorders	183,101	IL 183101	31/Jul/2015	Israel
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	206784	206784	31/Jan/2015	Israel
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	209738	209738	01/Feb/2019	Israel
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	221871	221871	01/Jul/2017	Israel
GW Pharma Limited	CBD / SAED'S combination	227298	227298	01/Mar/2018	Israel
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	229474	229474	01/Mar/2019	Israel
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	251526			Israel
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	283086			Israel
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	251529			Israel
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	281793			Israel
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	251530	251530	01/Feb/2020	Israel
GW Pharma Limited	Chemotherapeutic Agents	209739	209739	01/May/2016	Israel
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	217280	217280	01/Sep/2018	Israel
GW Pharma Limited	CBDV EPILEPSY	222132	222132	31/Jul/2018	Israel

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	231701			Israel
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	280294			Israel
GW Research Limited	Gel Formulation	263901			Israel
GW Research Limited	CBD for use in TSC tumours	271492			Israel
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	273583			Israel
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	274633			Israel
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	274769			Israel
GW Research Limited	Gel Formulation Packaging	275702			Israel
GW Research Limited	Modified Release Formulation	275703			Israel
GW Research Limited	THC/CBD Gel Formulation	275704			Israel
GW Research Limited	CBD STP epilepsy	276217			Israel
GW Research Limited	Project Nano CBD	278224			Israel
GW Research Limited	CBD-C4 first medical use	283234			Israel
GW Research Limited	GRIN2A epilepsy	283372			Israel
GW Pharma Limited	Supercritical CO2 extraction	1536810	50201290209752 7	01/Nov/2012	Italy
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	50201290202131 8	16/Nov/2011	Italy
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	50201090181407 2	02/Dec/2009	Italy
GW Pharma Limited	CBDA in treatment of motion sickness	03734779.6	EP1482917	08/May/2019	Italy
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	50200890168480 9	17/Sep/2008	Italy
GW Pharma Limited	CBC in the treatment of depression	04743065.7	50201490227112 7	09/Apr/2014	Italy
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	EP1765314	01/May/2019	Italy
GW Pharma Limited	THCV in treatment of appetite disorders	05803521.3	EP1811983	07/Oct/2020	Italy
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Italy
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	50201390219575 2	03/Jul/2013	Italy
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Italy
GW Pharma Limited	ADS patient diary	09169652.6	50201600002197 4	13/Jan/2016	Italy
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	EP08737019.3	EP2146731	16/Jan/2019	Italy

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	New use for cannabinoid-containing plant extracts	08762489.6	50201490226743 6	12/Mar/2014	Italy
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Italy
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Italy
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10180523.2	50201700005212 7	15/Feb/2017	Italy
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Italy
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	50201600004751 1	10/Feb/2016	Italy
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	50201700004658 5	01/Feb/2017	Italy
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	12731151.2	BP2726069	01/May/2019	Italy
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Italy
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	50201600000779 9	28/Oct/2015	Italy
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	12794753.9	BP2782563	25/Apr/2018	Italy
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Italy
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	50201600008174 1	13/Jul/2016	Italy
GW Pharma Limited	Supplementary Protection Certificate	UB2013001319	1319	28/Oct/2013	Italy
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Italy
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Italy
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	15185536.8	BP3028697	26/Dec/2018	Italy
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Italy
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	16777760.6	BP3355873	21/Oct/2020	Italy
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	50201490226203 6	12/Mar/2014	Italy
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	50201600006212 6	18/May/2016	Italy
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	14717843.8	BP2986289	31/Oct/2018	Italy

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	14732613.6	EP3010497	10/Apr/2019	Italy
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14732614.4	EP3010498	04/Mar/2020	Italy
GW Research Limited	7-OH-CBD DIABETES	15733513.4	EP3160456	25/Sep/2019	Italy
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	15733514.2	EP3160457	20/Nov/2019	Italy
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Italy
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Italy
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15784121.4	EP3206681	10/Apr/2019	Italy
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Italy
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16766051.3	EP3346999	19/Jun/2019	Italy
GW Pharma Limited	Supercritical CO2 extraction	2004-528675	4657716	07/Jan/2011	Japan
GW Pharma Limited	Supercritical CO2 extraction	2010-149763	5235206	05/Apr/2013	Japan
GW Pharma Limited	CBD in inhibition of tumour cell migration	2014-215666	JP6280489	26/Jan/2018	Japan
GW Pharma Limited	THCV in treatment of appetite disorders	2007-540721	4934048	24/Feb/2012	Japan
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	2009-514901	5286255	07/Jun/2013	Japan
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	2009-517376	5399898	01/Nov/2013	Japan
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	2010-503587	5775300	10/Jul/2015	Japan
GW Pharma Limited	Chemotherapeutic Agents	2011-512221	JP5674649	09/Jan/2015	Japan
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	2012-556592	5785569	31/Jul/2015	Japan
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	2014-510885	6147249	26/May/2017	Japan
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	2014-536325	6316193	06/Apr/2018	Japan
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	2014-541761	6338531	18/May/2018	Japan
GW Pharma Limited	Absence Seizures	2020-014572			Japan
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	2017-520526	6692805	17/Apr/2020	Japan
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020-016193			Japan
GW Pharma Limited	CBDA for use in epilepsy	2018-507504			Japan
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	2010-541094	5409650	15/Nov/2013	Japan
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	2011-512222	5611196	12/Sep/2014	Japan

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	2012-516867	5904938	25/Mar/2016	Japan
GW Pharma Limited	CBDV EPILEPSY	2013-501945	5918748	15/Apr/2016	Japan
GW Pharma Limited	CBD / SAED'S combination	2013-546766	6076259	20/Jan/2017	Japan
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	2014-532465	6326695	27/Apr/2018	Japan
GW Research Limited	Pharmaceutical compositions containing cannabinoids	2002-563905	4467883	05/Mar/2010	Japan
GW Research Limited	Pharmaceutical formulations (Sativex product)	2004-528678	4515908	21/May/2010	Japan
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	2007-526537	4920588	10/Feb/2012	Japan
GW Research Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	2015-515588	6284525	08/Feb/2018	Japan
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	2016-573558	6654282	03/Feb/2020	Japan
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	2019-211265			Japan
GW Research Limited	Absence Seizures	2016-573518	6655850	06/Feb/2020	Japan
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	2020-72217			Japan
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2017-520530	6656241	06/Feb/2020	Japan
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	2017-520535	6655076	04/Feb/2020	Japan
GW Research Limited	Dravet trilogy	2017-565998			Japan
GW Research Limited	Gel Formulation	2018-567205			Japan
GW Research Limited	CBD for use in TSC tumours	2019-571439			Japan
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020-517999			Japan
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020-526576			Japan
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020-529428			Japan
GW Research Limited	Gel Formulation Packaging	2020-536981			Japan
GW Research Limited	Modified Release Formulation	2020-536959			Japan
GW Research Limited	THC/CBD Gel Formulation	2020-536983			Japan
GW Research Limited	CBD STP epilepsy	2020-540552			Japan
GW Research Limited	Project Nano CBD	2020-560164			Japan
GW Research Limited	CBD-C4 first medical use	TBC			Japan
GW Research Limited	GRIN2A epilepsy	TBC			Japan
GW Pharma Limited	CBDV EPILEPSY	PCT/GB2011/050649	036044	17/Sep/2020	Kazakhstan
GW Pharma Limited	CBDV EPILEPSY	PCT/GB2011/050649	036044	17/Sep/2020	Kyrgyzstan
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP1372979.2	EP2858633	13/Jul/2016	Latvia

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Latvia
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Latvia
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Latvia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Latvia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Latvia
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Latvia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX	11906			Lebanon
GW Research Limited	CBD in epileptic spasms	11923			Lebanon
GW Research Limited	Microparticulate formulations	11928			Lebanon
GW Research Limited	CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF	11964			Lebanon
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	11977			Lebanon
GW Research Limited	(-)-cis-THC First Medical Use	12034			Lebanon
GW Research Limited	(+)-cis-THC First Medical Use	12032			Lebanon
GW Research Limited	(+)-trans-THC First Medical Use	12033			Lebanon
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	12056			Lebanon
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	12053			Lebanon
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	12055			Lebanon
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	12054			Lebanon
GW Research Limited	ORAL CANNABINOID FORMULATIONS	12090			Lebanon
GW Research Limited	EPDX DDI Study	485/IP			Lebanon
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Lithuania
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Lithuania
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Lithuania
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Lithuania
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Lithuania
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Lithuania
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Lithuania
GW Pharma Limited	Supercritical CO2 extraction	1536810	BP1536810	01/Nov/2012	Luxembourg
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Luxembourg
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Luxembourg
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Luxembourg

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Luxembourg
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Luxembourg
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	92233	92233	26/Aug/2013	Luxembourg
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	EP2448637	12/Mar/2014	Luxembourg
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	EP1542657	16/Nov/2011	Luxembourg
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Luxembourg
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	EP2314284	15/Feb/2017	Luxembourg
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Luxembourg
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Luxembourg
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Luxembourg
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Luxembourg
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Macedonia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Macedonia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Macedonia
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Macedonia
GW Pharma Limited	Chemotherapeutic Agents	PI 2010005535	MY-156264-A	29/Jan/2016	Malaysia
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	PI 2011006198	MY-156759-A	31/Mar/2016	Malaysia
GW Pharma Limited	CBDV EPILEPSY	PI2012004222	MY-162129-A	31/May/2017	Malaysia
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	PI2014000407	MY-171310-A	08/Oct/2019	Malaysia
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	EP2544682	10/Feb/2016	Malta
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Malta
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Malta
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Malta
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Malta
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Malta
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Malta
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	PA/A/2003/007215	236616	08/May/2006	Mexico
GW Pharma Limited	Supercritical CO2 extraction	PA/A/2005/001621	262155	13/Feb/2009	Mexico
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	PA/A/2005/001567	277949	09/Aug/2010	Mexico
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	PA/A/2006/014057	311516	19/Jul/2013	Mexico

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	THCV in treatment of appetite disorders	MX/A/2007/005626	296744	06/Mar/2012	Mexico
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	MX/A/2010/007073	334359	27/Oct/2015	Mexico
GW Pharma Limited	CBD / SAED'S combination	2013/007609	349027	07/Jul/2017	Mexico
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	MX/A/2014/006057	348564	20/Jun/2017	Mexico
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	MX/A/2014/014839	356052	11/May/2018	Mexico
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	MX/A/2016/016459	367338	15/Aug/2019	Mexico
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	MX/A/2019/008337			Mexico
GW Pharma Limited	Absence Seizures	MX/A/2016/016460			Mexico
GW Pharma Limited	Absence Seizures	MX/A/2020/003182			Mexico
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	MX/A/2017/004763	374007	23/Jul/2020	Mexico
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	MX/A/2020/006954			Mexico
GW Pharma Limited	USE OF CANNABINOID IN THE TREATMENT OF EPILEPSY	MX/A/2017/004762	374009	23/Jul/2020	Mexico
GW Pharma Limited	USE OF CANNABINOID IN THE TREATMENT OF EPILEPSY	MX/A/2020/006951			Mexico
GW Pharma Limited	USE OF CANNABINOID IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	MX/A/2017/004761	364633	03/May/2019	Mexico
GW Pharma Limited	CBDA for use in epilepsy	MX/A/2018/001472			Mexico
GW Pharma Limited	CBDA for use in epilepsy	MX/A/2021/000814			Mexico
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	MX/A/2012/000257	318952	02/Apr/2014	Mexico
GW Pharma Limited	CBDV EPILEPSY	MX/A/2012/011033	330328	27/May/2015	Mexico
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOID CANNABIVARIN (CBDV) AND CANNABIDIOL (CBD)	MX/A/2014/003310	367758	05/Sep/2019	Mexico
GW Research Limited	Dravet trilogy	MX/A/2017/016212			Mexico
GW Research Limited	Dravet trilogy	MX/A/2021/003331			Mexico
GW Research Limited	Gel Formulation	MX/A/2018/015699			Mexico
GW Research Limited	CBD for use in TSC tumours	MX/A/2019/014715			Mexico
GW Research Limited	CBD for use in TSC tumours	PCT/GB2018/051733			Mexico
GW Research Limited	USE OF CANNABINOID IN THE TREATMENT OF EPILEPSY	MX/A/2020/003934			Mexico
GW Research Limited	USE OF CANNABINOID IN THE TREATMENT OF EPILEPSY	MX/A/2020/005147			Mexico
GW Research Limited	USE OF CANNABINOID IN THE TREATMENT OF EPILEPSY	MX/A/2020/005719			Mexico
GW Research Limited	Gel Formulation Packaging	MX/A/2020/006964			Mexico

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	Modified Release Formulation	MX/A/2020/006957			Mexico
GW Research Limited	THC/CBD Gel Formulation	MX/A/2020/006965			Mexico
GW Research Limited	CBD STP epilepsy	MX/A/2020/007784			Mexico
GW Research Limited	Project Nano CBD	MX/A/2020/011163			Mexico
GW Research Limited	CBD-C4 first medical use	MX/A/2021/005919			Mexico
GW Research Limited	GRIN2A epilepsy	PCT/GB2019/053372			Mexico
GW Pharma Limited	CBDV EPILEPSY	201290975	036044	17/Sep/2020	Moldova
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Monaco
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Monaco
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Monaco
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Monaco
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Monaco
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Monaco
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Monaco
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Monaco
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Monaco
GW Pharma Limited	Supercritical CO2 extraction	EP1536810	BP1536810	01/Nov/2012	Netherlands
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	BP1542657	16/Nov/2011	Netherlands
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	BP1542984	02/Dec/2009	Netherlands
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	Netherlands
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Netherlands
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Netherlands
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	BP2037902	03/Jul/2013	Netherlands
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Netherlands
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Netherlands
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Netherlands
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Netherlands
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Netherlands
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Netherlands
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Netherlands
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Netherlands
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Netherlands
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	BP1542657	300572	15/Aug/2013	Netherlands

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Netherlands
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Netherlands
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Netherlands
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Netherlands
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Netherlands
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	BP2448637	12/Mar/2014	Netherlands
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Netherlands
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Netherlands
GW Research Limited	USE OF CANNABINOID IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Netherlands
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Netherlands
GW Pharma Limited	THCV in treatment of appetite disorders	554868	554868	12/Aug/2010	New Zealand
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	586648	586648	22/Mar/2013	New Zealand
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	589228	589228	03/Sep/2013	New Zealand
GW Pharma Limited	Chemotherapeutic Agents	589373	589373	03/Sep/2013	New Zealand
GW Pharma Limited	PHYTOCANNABINOID IN THE TREATMENT OF CANCER	602953	602953	06/Jan/2015	New Zealand
GW Pharma Limited	PHYTOCANNABINOID IN THE TREATMENT OF CANCER	629136	629136	01/Jul/2016	New Zealand
GW Pharma Limited	CBD / SAED'S combination	613307	613307	01/Mar/2016	New Zealand
GW Pharma Limited	CBD / SAED'S combination	709911	709911	24/Mar/2017	New Zealand
GW Pharma Limited	CANNABINOID FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	618246	618246	03/May/2016	New Zealand
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	727509			New Zealand
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	765223			New Zealand
GW Pharma Limited	Absence Seizures	727511			New Zealand
GW Pharma Limited	Absence Seizures	765231			New Zealand
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	730980			New Zealand
GW Pharma Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	768000			New Zealand
GW Pharma Limited	USE OF CANNABINOID IN THE TREATMENT OF EPILEPSY	730982			New Zealand

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	768001			New Zealand
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	730985			New Zealand
GW Pharma Limited	CBDA for use in epilepsy	739200			New Zealand
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	739933			New Zealand
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	597704	597704	02/Sep/2014	New Zealand
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	620838	620838	01/Dec/2015	New Zealand
GW Pharma Limited	CBDV EPILEPSY	602925	602925	03/Mar/2015	New Zealand
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	622424	622424	02/Feb/2016	New Zealand
GW Research Limited	Pharmaceutical compositions containing cannabinoids	527289	527289	08/Sep/2005	New Zealand
GW Research Limited	Dravet trilogy	738403			New Zealand
GW Research Limited	Dravet trilogy	775265			New Zealand
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	748016			New Zealand
GW Research Limited	CBDV patent in Autism	748021			New Zealand
GW Research Limited	Gel Formulation	749142			New Zealand
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	754352			New Zealand
GW Research Limited	CBD for use in TSC tumours	759615			New Zealand
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	763135			New Zealand
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	764569			New Zealand
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	764587			New Zealand
GW Research Limited	Gel Formulation Packaging	765835			New Zealand
GW Research Limited	Modified Release Formulation	765844			New Zealand
GW Research Limited	THC/CBD Gel Formulation	765839			New Zealand
GW Research Limited	CBD STP epilepsy	766517			New Zealand
GW Research Limited	Project Nano CBD	769785			New Zealand
GW Research Limited	CBD-C4 first medical use	776300			New Zealand
GW Research Limited	GRIN2A epilepsy	776600			New Zealand
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	EP2544682	10/Feb/2016	Norway
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Norway

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Sulingual application of cannabis (Pharmasol)	2013011	2013011	16/Jun/2015	Norway
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Norway
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Norway
GW Research Limited	Pharmaceutical compositions containing cannabinoids	20033556	334743	28/Mar/2014	Norway
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Norway
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Norway
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Norway
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX	2018655			Paraguay
GW Research Limited	Microparticulate formulations	2022938			Paraguay
GW Research Limited	CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF	2036977			Paraguay
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	2040196			Paraguay
GW Research Limited	(-)-cis-THC First Medical Use	2068167			Paraguay
GW Research Limited	(+)-cis-THC First Medical Use	2068171			Paraguay
GW Research Limited	(+)-trans-THC First Medical Use	2068174			Paraguay
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2076934			Paraguay
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2076926			Paraguay
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2076940			Paraguay
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2076931			Paraguay
GW Research Limited	ORAL CANNABINOID FORMULATIONS	2085961			Paraguay
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	1-2010-501375	1-2010-501375	11/Apr/2016	Philippines
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	1-2010-502652	1-2010-502652	24/Aug/2016	Philippines
GW Pharma Limited	Chemotherapeutic Agents	1-2010-502950	1-2010-502950	17/Jun/2015	Philippines
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	1-2011-502647	1-2011-502647	11/Feb/2016	Philippines
GW Pharma Limited	CBDV EPILEPSY	1-2012-501902	1-2012-501902	11/Apr/2017	Philippines
GW Pharma Limited	CBD / SAED'S combination	1/2013/501389	1/2013/501389	29/Oct/2018	Philippines
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIOL (CBDV) AND CANNABIDIOL (CBD)	1-2014-500452			Philippines
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	P-364177	216740	04/Oct/2013	Poland
GW Pharma Limited	Supercritical CO2 extraction	P-375357	205945	29/Dec/2009	Poland
GW Pharma Limited	Extraction of pharmaceutically active cannabinoids from plant materials	P-388837	226646	16/Feb/2017	Poland

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	P-375224	215220	21/Mar/2013	Poland
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Poland
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Poland
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	Poland
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Poland
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Poland
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Poland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Poland
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Poland
GW Pharma Limited	Supplementary Protection Certificate based on P-375224	0245/0215220	BP215220	10/Jan/2017	Poland
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Poland
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Poland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Poland
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Poland
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Poland
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Poland
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Poland
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Aug/2012	Portugal
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Portugal
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Portugal
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Portugal
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Portugal
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Portugal
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Portugal
GW Pharma Limited	SPC - Pharmaceutical formulations (Sativex product)	509	509	20/Mar/2013	Portugal
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Portugal
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Portugal

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Portugal
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Portugal
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Portugal
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Portugal
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Portugal
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Portugal
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Portugal
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Portugal
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Portugal
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Portugal
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Republic of Serbia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Republic of Serbia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Republic of Serbia
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Republic of Serbia
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Romania
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Romania
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Romania
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Romania
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Romania
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Romania
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Romania
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Romania
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Romania
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	2010132649	2503448	10/Jan/2014	Russian Federation
GW Pharma Limited	Chemotherapeutic Agents	2010154672	2543034	27/Feb/2015	Russian Federation
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	2012103603	2563143	20/Sep/2015	Russian Federation
GW Pharma Limited	CBDV EPILEPSY	201290975	036044	17/Sep/2020	Russian Federation

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020114753			Russian Federation
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020119390			Russian Federation
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020121661			Russian Federation
GW Research Limited	Gel Formulation Packaging	2020125284			Russian Federation
GW Research Limited	Modified Release Formulation	2020125295			Russian Federation
GW Research Limited	THC/CBD Gel Formulation	2020125315			Russian Federation
GW Research Limited	CBD STP epilepsy	2020127876			Russian Federation
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	San Marino
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	San Marino
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	San Marino
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	San Marino
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	201004196-0	162310	31/Jan/2013	Singapore
GW Pharma Limited	Chemotherapeutic Agents	201009655-0	167613	15/Jul/2013	Singapore
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	201109404-2	176914	17/Sep/2014	Singapore
GW Pharma Limited	CBDV EPILEPSY	10201502480X	10201502480X	21/Nov/2019	Singapore
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	10202103035Y			Singapore
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Slovak Republic
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Slovak Republic
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	EP1976506	26/Jun/2019	Slovak Republic
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Slovak Republic
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	PDO 5023-2012	DO144	10/Dec/2012	Slovak Republic
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	Slovak Republic
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Slovak Republic
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	Slovak Republic
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	Slovak Republic
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	Slovak Republic

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Slovenia
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Slovenia
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Slovenia
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Slovenia
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Slovenia
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Slovenia
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Slovenia
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Slovenia
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Slovenia
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	2003/06074	2003/06074	26/Jan/2005	South Africa
GW Pharma Limited	Supercritical CO2 extraction	2005/01169	2005/01169	27/Dec/2006	South Africa
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	2005/01228	2005/01228	30/Aug/2006	South Africa
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	2006/10242	2006/10242	28/May/2008	South Africa
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	2010/05443	2010/05443	28/Apr/2011	South Africa
GW Pharma Limited	Chemotherapeutic Agents	2010/08558	2010/08558	26/Nov/2014	South Africa
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	2012/00373	2012/00373	26/Sep/2012	South Africa
GW Pharma Limited	CBDV EPILEPSY	2012/08141	2012/08141	26/Jun/2013	South Africa
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	2014/02207	2014/02207	23/Dec/2014	South Africa
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020/02365			South Africa
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020/02768			South Africa
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2020/02964			South Africa
GW Research Limited	Gel Formulation Packaging	2020/04049			South Africa
GW Research Limited	Modified Release Formulation	2020/04050			South Africa
GW Research Limited	THC/CBD Gel Formulation	2020/04051			South Africa
GW Research Limited	CBD STP epilepsy	2020/04733			South Africa
GW Research Limited	Project Nano CBD	2020/06655			South Africa
GW Research Limited	CBD-C4 first medical use	2021/03219			South Africa
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	10-2003-7010780	10-0886668	25/Feb/2009	South Korea
GW Pharma Limited	Supercritical CO2 extraction	10-2005-7002527	10-1113162	31/Jan/2012	South Korea
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10-2005-7002528	10-1008609	10/Jan/2011	South Korea
GW Pharma Limited	THCV in treatment of appetite disorders	10-2012-7003649	10-1221505	07/Jan/2013	South Korea
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	10-2010-7017111	10-1631518	13/Jun/2016	South Korea

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	10-2011-7000057	10-1801639	21/Nov/2017	South Korea
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10-2012-7003123	10-1727000	10/Apr/2017	South Korea
GW Pharma Limited	CBDV EPILEPSY	10-2012-7028091	10-1849703	11/Apr/2018	South Korea
GW Pharma Limited	CBD / SAED'S combination	2013-7020543	1853634	25/Apr/2018	South Korea
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	2014-7009091	2107715	28/Apr/2020	South Korea
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	10-2020-7011141			South Korea
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	10-2020-7015573			South Korea
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	10-2020-7017717			South Korea
GW Research Limited	Gel Formulation Packaging	10-2020-7021893			South Korea
GW Research Limited	Modified Release Formulation	10-2020-7021894			South Korea
GW Research Limited	THC/CBD Gel Formulation	10-2020-7021895			South Korea
GW Research Limited	CBD STP epilepsy	10-2020-7023811			South Korea
GW Research Limited	Project Nano CBD	10-2020-7033611			South Korea
GW Research Limited	CBD-C4 first medical use	PCT/GB2019/053284			South Korea
GW Research Limited	GRIN2A epilepsy	PCT/GB2019/053372			South Korea
GW Pharma Limited	Supercritical CO2 extraction	03787897.2	1536810	01/Nov/2012	Spain
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	ES 2337460 T3	02/Dec/2009	Spain
GW Pharma Limited	CBDA in treatment of motion sickness	03734779.6	BP1482917	08/May/2019	Spain
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	Spain
GW Pharma Limited	CBC in the treatment of depression	04743065.7	1644349	09/Apr/2014	Spain
GW Pharma Limited	TECV in treatment of appetite disorders	05803521.3	BP1811983	07/Oct/2020	Spain
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	Spain
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Spain
GW Pharma Limited	ADS patient diary	09169652.6	BP2123318	13/Jan/2016	Spain
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	EP08737019.3	BP2146731	16/Jan/2019	Spain
GW Pharma Limited	New use for cannabinoid-containing plant extracts	08762489.6	2182940	12/Mar/2014	Spain
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Spain
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Spain
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Spain
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	C201200015	C201200015	26/Jul/2013	Spain
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Spain
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	12731151.2	BP2726069	01/May/2019	Spain

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Spain
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Spain
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	12794753.9	BP2782563	25/Apr/2018	Spain
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Spain
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Spain
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Spain
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Spain
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	15185536.8	BP3028697	26/Dec/2018	Spain
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Spain
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	16777760.6	BP3355873	21/Oct/2020	Spain
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Spain
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Spain
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Spain
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Spain
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Spain
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Spain
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Spain
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	14717843.8	BP2986289	31/Oct/2018	Spain
GW Research Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	14732613.6	BP3010497	10/Apr/2019	Spain
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14732614.4	BP3010498	04/Mar/2020	Spain
GW Research Limited	7-OH-CBD DIABETES	15733513.4	BP3160456	25/Sep/2019	Spain
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	15733514.2	BP3160457	20/Nov/2019	Spain
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Spain
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Spain

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15784121.4	BP3206681	10/Apr/2019	Spain
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Spain
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16766051.3	BP3346999	19/Jun/2019	Spain
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	01/Nov/2012	Sweden
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	Sweden
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	Sweden
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Sweden
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Sweden
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Sweden
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Sweden
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	1290014-8	1542657	27/Nov/2012	Sweden
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Sweden
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Sweden
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Sweden
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Sweden
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Sweden
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Sweden
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Sweden
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Sweden
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Sweden
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Sweden
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Sweden
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Sweden
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Sweden
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Sweden
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Sweden
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Sweden

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Sweden
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Sweden
GW Pharma Limited	Hot gas extraction method	1385595	1385595	27/Jul/2012	Switzerland
GW Pharma Limited	Supercritical CO2 extraction	1536810	1536810	18/Dec/2012	Switzerland
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	1542984	02/Dec/2009	Switzerland
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	Switzerland
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	2037902	03/Jul/2013	Switzerland
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Switzerland
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	Switzerland
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Switzerland
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	Switzerland
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	Switzerland
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	Switzerland
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Switzerland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	BP2609928	17/Jul/2019	Switzerland
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	BP2858633	13/Jul/2016	Switzerland
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	1542657	CO1542657/01	31/Mar/2016	Switzerland
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	3157511	25/Apr/2018	Switzerland
GW Pharma Limited	Absence Seizures	15732887.3	BP3157512	25/Apr/2018	Switzerland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	BP3095452	17/Jul/2019	Switzerland
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	2448637	12/Mar/2014	Switzerland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Switzerland
GW Research Limited	Pharmaceutical formulations (Sativex product)	03787900.4	1542657	16/Nov/2011	Switzerland
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	BP1765314	01/May/2019	Switzerland
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	Switzerland
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	Switzerland
GW Research Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Switzerland
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Switzerland

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Switzerland
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Switzerland
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	97151656	I519299	01/Feb/2016	Taiwan
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations cannabinoids in combination with non-cannabinoid	98118351	1445531	21/Jul/2014	Taiwan
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	99121811	I 461191	21/Nov/2014	Taiwan
GW Pharma Limited	CBDV EPILEPSY	100108735	I583374	21/May/2017	Taiwan
GW Pharma Limited	CBD / SAED'S combination	100145265	I532479	11/May/2016	Taiwan
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	101134706	I577373	11/Apr/2017	Taiwan
GW Pharma Limited	Chemotherapeutic Agents	98118352	1469777	21/Jan/2015	Taiwan
GW Research Limited	Pharmaceutical compositions containing cannabinoids	91102626	222882	01/Nov/2004	Taiwan
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX	109114571			Taiwan
GW Research Limited	CBD in epileptic spasms	109117081			Taiwan
GW Research Limited	Microparticulate formulations	109118089			Taiwan
GW Research Limited	CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF	109124356			Taiwan
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	109125384			Taiwan
GW Research Limited	(-)-cis-THC First Medical Use	109136956			Taiwan
GW Research Limited	(+)-cis-THC First Medical Use	109136955			Taiwan
GW Research Limited	(+)-trans-THC First Medical Use	109136954			Taiwan
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	109140412			Taiwan
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	109140413			Taiwan
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	109140701			Taiwan
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	109140702			Taiwan
GW Research Limited	ORAL CANNABINOID FORMULATIONS	109145002			Taiwan
GW Research Limited	EPDX DDI Study	110106939			Taiwan
GW Pharma Limited	CBDV EPILEPSY	201290975	036044	17/Sep/2020	Tajikistan
GW Pharma Limited	Supercritical CO2 extraction	1536810	2012/12526	01/Nov/2012	Turkey
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	03787900.4	2012/01679	16/Nov/2011	Turkey
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	2320881	20/Sep/2017	Turkey
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	Turkey

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	2332533	22/Aug/2018	Turkey
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	TR 2017 06225 T4	01/Feb/2017	Turkey
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	2782568	28/Oct/2015	Turkey
GW Pharma Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	TR 2016 09966 T4	13/Jul/2016	Turkey
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	TR 2014 05518 T4	12/Mar/2014	Turkey
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	2249848	18/May/2016	Turkey
GW Research Limited	Cannabinoid extracts as neuroprotectants	07704916.1	TR 2019 14473	26/Jun/2019	Turkey
GW Research Limited	Pharmaceutical formulations (Sativex product)	10180523.2	2017 07022	15/Feb/2017	Turkey
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	BP3206715	27/May/2020	Turkey
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	BP3206716	29/Jul/2020	Turkey
GW Research Limited	CBDA for use in epilepsy	16747593.8	BP3334422	01/Jul/2020	Turkey
GW Pharma Limited	CBDV EPILEPSY	201290975	036044	17/Sep/2020	Turkmenistan
GW Research Limited	Project Nano CBD	P6001496/2020			United Arab Emirates
GW Research Limited	CBD-C4 first medical use	P6000829/2021			United Arab Emirates
GW Pharma Limited	Pharmaceutical compositions containing cannabinoids	0203527.7	GB2380129	11/Aug/2004	United Kingdom
GW Pharma Limited	CBDA in treatment of motion sickness	0206183.6	GB2384707	16/Nov/2005	United Kingdom
GW Pharma Limited	Hot gas extraction method	0210403.2	GB2376464	17/Nov/2004	United Kingdom
GW Pharma Limited	Hot gas extraction method	0409234.2	GB2400319	08/Jun/2005	United Kingdom
GW Pharma Limited	Hot gas extraction method	0409385.2	GB2400320	08/Jun/2005	United Kingdom
GW Pharma Limited	Supercritical CO2 extraction	0218901.7	GB2391865	01/Jun/2005	United Kingdom
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	0218930.6	GB2392093	08/Mar/2006	United Kingdom
GW Pharma Limited	Cannabinoid purification method (CBD)	0222078.8	GB2393182	14/Mar/2007	United Kingdom
GW Pharma Limited	ADS patient diary	03708317.7	BP1478420	09/Sep/2009	United Kingdom
GW Pharma Limited	Supercritical CO2 extraction	03787897.2	BP1536810	01/Aug/2012	United Kingdom
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	03750947.8	BP1542984	02/Dec/2009	United Kingdom
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	0504777.4	GB2408978	05/Apr/2006	United Kingdom
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	0412753.6	GB2414933	15/Jul/2009	United Kingdom
GW Pharma Limited	CBDA in treatment of motion sickness	03734779.6	BP1482917	08/May/2019	United Kingdom
GW Pharma Limited	THCV in treatment of appetite disorders	0515704.5	GB2434097	19/May/2010	United Kingdom
GW Pharma Limited	CBD in inhibition of tumour cell migration	EP05788521.2	BP1802274	17/Sep/2008	United Kingdom
GW Pharma Limited	CBC in the treatment of depression	04743065.7	BP1644349	09/Apr/2014	United Kingdom
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	0601013.6	GB2434312	29/Jun/2011	United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Treatment of Rheumatoid Arthritis (Sativex)	05749393.4	EP1765314	01/May/2019	United Kingdom
GW Pharma Limited	THCV in treatment of appetite disorders	05803521.3	BP1811983	07/Oct/2020	United Kingdom
GW Pharma Limited	New pharmaceutical formulation	0713175.8	GB2450753	18/Jul/2012	United Kingdom
GW Pharma Limited	New use for cannabinoids	0801051.4	GB2459637	06/Jun/2012	United Kingdom
GW Pharma Limited	CBC plants	0806553.4	GB2459125	02/Jan/2013	United Kingdom
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	07704916.1	BP1976506	26/Jun/2019	United Kingdom
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	07733222.9	BP2037901	08/Jan/2014	United Kingdom
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	07733311.0	BP2037902	03/Jul/2013	United Kingdom
GW Pharma Limited	Chemotherapeutic Agents	09757810.8	BP2320881	20/Sep/2017	United Kingdom
GW Pharma Limited	ADS patient diary	09169652.6	BP2123318	13/Jan/2016	United Kingdom
GW Pharma Limited	New use for cannabinoid-containing plant extract (TRP channels)	EP08737019.3	BP2146731	16/Jan/2019	United Kingdom
GW Pharma Limited	New use for cannabinoid-containing plant extracts	08762489.6	BP2182940	12/Mar/2014	United Kingdom
GW Pharma Limited	Phytocannabinoids in the treatment of cancer	1718726.1	GB2554592	11/Jul/2018	United Kingdom
GW Pharma Limited	CBDA in treatment of motion sickness	10180470.6	BP2275097	07/Aug/2019	United Kingdom
GW Pharma Limited	Supercritical CO2 extraction	10180464.9	BP2311475	31/Aug/2016	United Kingdom
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	10180523.2	BP2314284	15/Feb/2017	United Kingdom
GW Pharma Limited	Cannabinoid extracts as neuroprotectants	10189019.2	BP2332533	22/Aug/2018	United Kingdom
GW Pharma Limited	Pharmaceutical formulations (Sativex product)	SPC/GB10/049	SPC/GB/10/049	12/Dec/2018	United Kingdom
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	EP11709175.1	BP2544682	10/Feb/2016	United Kingdom
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	1108506.5	GB2491118	30/Dec/2015	United Kingdom
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	1512357.3	GB2524689	27/Jan/2016	United Kingdom
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	1120067.2	GB2496688	29/Jun/2016	United Kingdom
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	12722495.4	BP2709604	01/Feb/2017	United Kingdom
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	12731151.2	BP2726069	01/May/2019	United Kingdom
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	1211639.8	GB2492487	16/Sep/2015	United Kingdom
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	12780523.2	BP2768493	31/Jul/2019	United Kingdom
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF BREAST CANCER	1218732.4	GB2495841	10/Feb/2016	United Kingdom
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	12795839.5	BP2782568	28/Oct/2015	United Kingdom
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	12794753.9	BP2782563	25/Apr/2018	United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	13152600.6	EP2609928	17/Jul/2019	United Kingdom
GW Pharma Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	GB1310909.5	GB2516814	31/Aug/2016	United Kingdom
GW Pharma Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	15732886.5	EP3157511	25/Apr/2018	United Kingdom
GW Pharma Limited	Absence Seizures	15732887.3	EP3157512	25/Apr/2018	United Kingdom
GW Pharma Limited	TETRAHYDROCANNABIVARIN (THCV) FOR USE IN THE PROTECTION OF PANCREATIC ISLET CELLS	15185536.8	EP3028697	26/Dec/2018	United Kingdom
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	16167562.4	EP3095452	17/Jul/2019	United Kingdom
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	16777760.6	EP3355873	21/Oct/2020	United Kingdom
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	0810195.8	GB2471987	22/Feb/2012	United Kingdom
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	1105991.2	GB2478072	26/Dec/2012	United Kingdom
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	1107850.8	GB2478074	26/Dec/2012	United Kingdom
GW Pharma Limited	Chemotherapeutic Agents	0810203.0	GB2460672	04/Jan/2012	United Kingdom
GW Pharma Limited	Chemotherapeutic Agents	1101072.5	GB2475183	23/Nov/2011	United Kingdom
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	1012953.4	GB2468828	07/Nov/2012	United Kingdom
GW Pharma Limited	CBDV EPILEPSY	1005364.3	GB2479153	19/Mar/2014	United Kingdom
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	1010897.5	GB2471565	04/Jul/2012	United Kingdom
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	10734541.5	EP2448637	12/Mar/2014	United Kingdom
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	08869534.1	EP2249848	18/May/2016	United Kingdom
GW Pharma Limited	CBDV EPILEPSY	1100042.9	GB2487183	03/Oct/2018	United Kingdom
GW Pharma Limited	CBD / SAED'S combination	1100043.7	GB2487712	28/Oct/2015	United Kingdom
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	1116789.7	GB2495118	18/May/2016	United Kingdom
GW Pharma Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	1307047.9	GB2513167	02/Mar/2016	United Kingdom
GW Research Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	EP13729798.2	EP2858633	13/Jul/2016	United Kingdom
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	1406473.7	GB2516335	08/Feb/2017	United Kingdom
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	14717843.8	EP2986289	31/Oct/2018	United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	GB1410771.8	GB2530001	16/Jan/2019	United Kingdom
GW Research Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	14732613.6	EP3010497	10/Apr/2019	United Kingdom
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14732614.4	EP3010498	04/Mar/2020	United Kingdom
GW Research Limited	7-OH-CBD DIABETES	15733513.4	EP3160456	25/Sep/2019	United Kingdom
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	15733514.2	EP3160457	20/Nov/2019	United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	GB1515986.6	GB2542155	01/Aug/2018	United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15784107.3	EP3206715	27/May/2020	United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ATONIC SEIZURES IN LENNOX-GASTAUT SYNDROME	EP15784111.5	EP3206716	29/Jul/2020	United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15784121.4	EP3206681	10/Apr/2019	United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF STURGE WEBER SYNDROME	GB1605448.8	GB2548873	02/Dec/2020	United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER	GB1606097.2	GB2549277	17/Feb/2021	United Kingdom
GW Research Limited	CBDV patent in Autism	GB1606098.0	GB2549278	17/Feb/2021	United Kingdom
GW Research Limited	Gel Formulation	GB1611544.6	GB2551985	30/Jan/2019	United Kingdom
GW Research Limited	CBDA for use in epilepsy	16747593.8	EP3334422	01/Jul/2020	United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16766051.3	EP3346999	19/Jun/2019	United Kingdom
GW Research Limited	Oral Aqueous Solution	GB1702613.9			United Kingdom
GW Research Limited	CBD for use in TSC tumours	GB1710042.1	GB2564383	21/Apr/2021	United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER	GB1711190.7			United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GB1718862.4			United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GB1720020.5			United Kingdom
GW Research Limited	Gel Formulation Packaging	GB1800072.9			United Kingdom
GW Research Limited	Modified Release Formulation	GB1800073.7	GB2572125	13/Jan/2021	United Kingdom
GW Research Limited	THC/CBD Gel Formulation	GB1800074.5	GB2572126	13/Jan/2021	United Kingdom
GW Research Limited	CBD_STP epilepsy	GB1801158.5			United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GB1816037.4			United Kingdom
GW Research Limited	CBD-C4 first medical use	GB1818935.7			United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	GRIN2A epilepsy	GB1819573.5			United Kingdom
GW Research Limited	CBD COMORBIDITIES	GB1900797.0			United Kingdom
GW Research Limited	CBD EIFMS	GB1902427.2			United Kingdom
GW Research Limited	CBD plus antibiotic	1903002.2			United Kingdom
GW Research Limited	Project Nano CBD	1905876.7			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX	1906261.1			United Kingdom
GW Research Limited	CBD in epileptic spasms	1907283.4			United Kingdom
GW Research Limited	Microparticulate formulations	GB1907786.6			United Kingdom
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	1910803.4			United Kingdom
GW Research Limited	THCV in PD dyskinesia	1912244.9			United Kingdom
GW Research Limited	(-)-cis-THC First Medical Use	1915513.4			United Kingdom
GW Research Limited	(+)-cis-THC First Medical Use	1915514.2			United Kingdom
GW Research Limited	(+)-trans-THC First Medical Use	1915515.9			United Kingdom
GW Research Limited	CBDV nano	1915516.7			United Kingdom
GW Research Limited	CBD use in Fragile X syndrome	1915517.5			United Kingdom
GW Research Limited	CBD use in temporal lobe epilepsy	1915519.1			United Kingdom
GW Research Limited	CBD use in absence epilepsy	1915522.5			United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	2009321.7			United Kingdom
GW Research Limited	Novel Compounds	2011084.7			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011120.9			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INJURY	2011123.3			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011125.8			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES	2011128.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011131.6			United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011134.0			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES	2011139.9			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH MOVEMENT DISORDERS	2011142.3			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011146.4			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INJURY	2011150.6			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011152.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011155.5			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HETEROPLASIA	2011119.1			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH AURICULOTEMPORAL SYNDROME	2011122.5			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011124.1			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH MULTIFOCAL EPILEPSY	2011126.6			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011127.4			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011130.8			United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011133.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011137.3			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO BRAIN INJURY	2011140.7			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011141.5			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAIN	2011143.1			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH HERPES SIMPLEX VIRUS	2011148.0			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH STROKE	2011149.8			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH SHAKEN BABY SYNDROME	2011151.4			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011153.0			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH ENCEPHALITIS	2011154.8			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011156.3			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011158.9			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011159.7			United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011160.5			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011162.1			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011161.3			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011163.9			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011168.8			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011171.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011164.7			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011166.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011169.6			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011170.4			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011173.8			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011175.3			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011178.7			United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011172.0			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2011174.6			United Kingdom
GW Research Limited	METHOD OF PREPARING CANNABINOIDS	2013765.9			United Kingdom
GW Research Limited	USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES	2014250.1			United Kingdom
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	GB2014723.7			United Kingdom
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2018129.3			United Kingdom
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2018130.1			United Kingdom
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2018135.0			United Kingdom
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2018139.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH EPILEPSY SYNDROMES	2019301.7			United Kingdom
GW Research Limited	CANNABINOID DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF	2019784.4			United Kingdom
GW Research Limited	NOVEL COMPOUNDS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF	2019786.9			United Kingdom
GW Research Limited	A METHOD FOR EVALUATING THE PRO- OR ANTI CONVULSIVE PROPERTIES OF TEST COMPOUNDS	2019787.7			United Kingdom
GW Research Limited	Low conc CBD formulation	2020117.4			United Kingdom
GW Research Limited	IDENTIFICATION AND TREATMENT OF PATIENTS WITH EPILEPSY	2020274.3			United Kingdom
GW Research Limited	Use of cannabidivarin in the treatment of seizures associated with canine epilepsy	2102010.2			United Kingdom
GW Research Limited	USE OF CANNABIDIOL AND CLOBAZAM IN THE TREATMENT OF CHILDHOOD-ONSET EPILEPSY SYNDROMES	2102694.3			United Kingdom
GW Research Limited	EPDX DDI Study	2102853.5			United Kingdom
GW Research Limited	NOVEL COMPOUNDS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF	2104278.3			United Kingdom
GW Research Limited	NOVEL COMPOUND	2106789.7			United Kingdom
GW Research Limited	NOVEL COMPOUNDS	2106788.9			United Kingdom
GW Research Limited	NOVEL RESORCINOLS, METHODS FOR THEIR MANUFACTURE, AND USES THEREOF	2106787.1			United Kingdom

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	RESORCINOL DERIVATIVE AS A PHARMACEUTICALLY ACTIVE COMPOUND AND METHOD OF PREPARATION THEREOF	2106786.3			United Kingdom
GW Pharma Limited	Hot gas extraction method	10/476,718	7,622,140	24/Nov/2009	USA
GW Pharma Limited	Hot gas extraction method	12/618,347	9,034,395	19/May/2015	USA
GW Pharma Limited	Hot gas extraction method	14/674,098	10,195,159	05/Feb/2019	USA
GW Pharma Limited	Supercritical CO2 extraction	10/218,972	7,344,736	18/Mar/2008	USA
GW Pharma Limited	CBDA in treatment of motion sickness	10/502,822	8,034,843	11/Oct/2011	USA
GW Pharma Limited	CBDA in treatment of motion sickness	16/532,985			USA
GW Pharma Limited	ADS patient diary	12/430,425	8,061,351	22/Nov/2011	USA
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	10/528,951	7,700,368	20/Apr/2010	USA
GW Pharma Limited	Cannabinoid purification method (Generic & THC)	12/714,907	8,846,409	30/Sep/2014	USA
GW Pharma Limited	CBC in the treatment of depression	10/561,756	8,470,874	25/Jun/2013	USA
GW Pharma Limited	THCV in treatment of appetite disorders	11/667,890	9,168,278	27/Oct/2015	USA
GW Pharma Limited	THCV in treatment of appetite disorders	US14/851,378	US9,669,002	06/Jun/2017	USA
GW Pharma Limited	Pharmaceutical compositions comprising cannabigerol	11/760,364	8,481,085	09/Jul/2013	USA
GW Pharma Limited	CBD in inhibition of tumour cell migration	US16/143,094			USA
GW Pharma Limited	Supercritical CO2 extraction	16/904,643			USA
GW Pharma Limited	Zero cannabinoid plant	12/156,460	9,035,130	19/May/2015	USA
GW Pharma Limited	Chemotherapeutic Agents	17/102,109			USA
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	14/579,061	9,522,123	20/Dec/2016	USA
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	13/634,343	8,790,719	29/Jul/2014	USA
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	14/260,876	9,675,654	13/Jun/2017	USA
GW Pharma Limited	PHYTOCANNABINOIDS IN THE TREATMENT OF CANCER	15/620,435			USA
GW Pharma Limited	CANNABINOIDS FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN	14/118,563	9,895,342	20/Feb/2018	USA
GW Pharma Limited	Cannabinoids for use in the treatment of neuropathic pain (High CBD extract)	16/142,394			USA
GW Pharma Limited	Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders	14/128,208	US 10,258,580	16/Apr/2019	USA
GW Pharma Limited	PHYTOCANNABINOIDS FOR USE IN THE TREATMENT OF INTESTINAL INFLAMMATORY DISEASES	14/359,192	US 9,421,187	23/Aug/2016	USA
GW Pharma Limited	USE OF PHYTOCANNABINOIDS FOR INCREASING RADIOSENSITIVITY IN THE TREATMENT OF CANCER	US15/969,422	10,758,514	01/Sep/2020	USA
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	15/757,899	10,653,641	19/May/2020	USA
GW Pharma Limited	USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS	16/845,204			USA

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	CANNABINOIDS IN SKIN INFLAMMATION	15/763,186			USA
GW Pharma Limited & Tyco Electronics UK Limited	Vaporiser apparatus with resistors	10/494,136	7,088,914	08/Aug/2006	USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	Use of cannabinoids in combination with an anti-psychotic medicament	12/811,393	9,017,737	28/Apr/2015	USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	Anti-tumoural effects of cannabinoid combinations	12/996,124	8,632,825	21/Jan/2014	USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	CBDV EPILEPSY	13/075,873	9,125,859	08/Sep/2015	USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	CBDV EPILEPSY	14/685,753	10,799,467	13/Oct/2020	USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	CBDV EPILEPSY	17/012,448			USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	CBD / SAED'S combination	13/977,766			USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	CBD / SAED'S combination	17/179,331			USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	14/345,968	10,729,665	04/Aug/2020	USA
GW Pharma Limited & Otsuka Pharmaceutical Co Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	16/709,401			USA
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	13/380,305	9,066,920	30/Jun/2015	USA
GW Pharma Limited	Secure container for holding liquid medicaments	29/252,892	D559,396	08/Jan/2008	USA
GW Pharma Limited	hand-held electronic device	29/252,926	D562,316	19/Feb/2008	USA
GW Research Limited	Pharmaceutical compositions containing cannabinoids	09/951,022	7,025,992	11/Apr/2006	USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	10/218,989	6,946,150	20/Sep/2005	USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	11/229,052	7,709,536	04/May/2010	USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	16/417,860	10,538,373	21/Jan/2020	USA
GW Research Limited	Treatment of cancer pain (Sativex)	11/115,983	7,968,594	28/Jun/2011	USA
GW Research Limited	Treatment of cancer pain (Sativex)	13/093,911	8,771,760	08/Jul/2014	USA
GW Research Limited	Treatment of Rheumatoid Arthritis (Sativex)	US16/562,515			USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	12/704,729	8,211,946	03/Jul/2012	USA
GW Research Limited	Cannabinoid extracts as neuroprotectants	12/087,847	8,673,368	18/Mar/2014	USA
GW Research Limited	Cannabinoid extracts as neuroprotectants	14/163,019	9,205,063	08/Dec/2015	USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	13/486,227	8,603,515	10/Dec/2013	USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	14/074,067	9,029,423	12/May/2015	USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	US14/685,707	US 10,179,683	15/Jan/2019	USA

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	SYNERGISTIC THERAPIES FOR NEUROPROTECTION	14/405,950	10,220,005	05/Mar/2019	USA
GW Research Limited	TETRAHYDROCANNABIVARIN FOR USE IN THE TREATMENT OF NAUSEA AND VOMITING	US14/785,055	9,675,579	13/Jun/2017	USA
GW Research Limited	THE USE OF PHYTOCANNABINOIDS IN THE TREATMENT OF OVARIAN CARCINOMA	14/899,613	US 10,098,867	16/Oct/2018	USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	14/741,783	9,474,726	25/Oct/2016	USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/284,766	US 9,949,936	24/Apr/2018	USA
GW Research Limited	Absence Seizures	14/741,829			USA
GW Research Limited	ACTIVE PHARMACEUTICAL INGREDIENT (API) COMPRISING CANNABINOIDS FOR USE IN THE TREATMENT OF CANCER	US15/321,766	9,962,341	08/May/2018	USA
GW Research Limited	7-OH-CBD DIABETES	US15/321,778	10,039,724	07/Aug/2018	USA
GW Research Limited	USE OF 7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) IN THE TREATMENT OF EPILEPSY	US16/591,702			USA
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	14/881,954	10,918,608	16/Feb/2021	USA
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	17/147,005			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	14/881,969	10,111,840	30/Oct/2018	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	US15/449,402	10,092,525	09/Oct/2018	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	US15/449,535	10,137,095	27/Nov/2018	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/198,141	US10,849,860	01/Dec/2020	USA
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	15/519,233	10,765,643	08/Sep/2020	USA
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF NOCTURNAL SNORING	15/519,244			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF DEGENERATIVE SKELETAL MUSCLE DISEASES	15/518,297	US10,226,433	12/Mar/2019	USA
GW Research Limited	Dravet trilogy	15/183,947	10,709,671	14/Jul/2020	USA
GW Research Limited	Dravet trilogy	US 16/893,018			USA
GW Research Limited	CBDA for use in epilepsy	15/751,563			USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/449,084	US 9,956,183	01/May/2018	USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/449,124	US 9,956,184	01/May/2018	USA

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/449,185	US 9,949,937	24/Apr/2018	USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/449,204	US 9,956,186	01/May/2018	USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/449,177	US 9,956,185	01/May/2018	USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	US15/948,412	10,603,288	31/Mar/2020	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/090,039	10,583,096	10/Mar/2020	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/737,707			USA
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	16/092,560	10,898,462	26/Jan/2021	USA
GW Research Limited	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF AUTISM SPECTRUM DISORDER AND ASSOCIATED DISORDERS	17/128,458			USA
GW Research Limited	CBDV patent in Autism	16/092,374			USA
GW Research Limited	Parenteral Formulations	16/314,583			USA
GW Research Limited	Oral Cannabinoid Formulations (Low Ethanol)	16/314,569			USA
GW Research Limited	Gel Formulation	15/640,033			USA
GW Research Limited	MULTIPLE MYELOMA	16/328,209			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF ANGELMAN SYNDROME	16/467,639			USA
GW Research Limited	Oral Aqueous Solution	16/486,750			USA
GW Research Limited	LEUKAEMIA	16/488,821	11,000,486	11/May/2021	USA
GW Research Limited	LEUKAEMIA	17/231,625			USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	16/791,940			USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TREATMENT-RESISTANT EPILEPSY	16/989,605			USA
GW Research Limited	CBD for use in TSC tumours	16/624,106			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE OR DISORDER	16/629,722			USA

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/651,751			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/764,701			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/570,220	10,709,673	14/Jul/2020	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/768,241			USA
GW Research Limited	Gel Formulation Packaging	16/959,350			USA
GW Research Limited	Modified Release Formulation	16/959,354			USA
GW Research Limited	THC/CBD Gel Formulation	16/959,357			USA
GW Research Limited	CBD STP epilepsy	16/960,665			USA
GW Research Limited	Project Nano CBD	17/011,715			USA
GW Research Limited	Project Nano CBD	17/050,956			USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	16/701,405	10,807,777	20/Oct/2020	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/678,961	10,709,674	14/Jul/2020	USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	16/911,914	10,966,939	06/Apr/2021	USA
GW Research Limited	CBD-C4 first medical use	17/296,066			USA
GW Research Limited	Pharmaceutical formulations (Sativex product)	17/060,700			USA
GW Research Limited	USE OF CANNABIDIOL IN THE REDUCTION OF CONVULSIVE SEIZURE FREQUENCY IN TRBTMENT-RESISTANT EPILEPSY	17/119,873			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	17/198,965			USA
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	16/935,005			USA
GW Research Limited	USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY	17/025,130			USA
GW Research Limited	CANNABINOID FOMULATIONS	17/068,326			USA
GW Research Limited	USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSY	17/147,005			USA
GW Research Limited	EPDX DDI Study	17/188,766			USA
GW Research Limited	Pharmaceutical formulations	10/468,041	10,004,684	26/Jun/2018	USA
GW Research Limited	Use of Cannabinoids in the Treatment of Epilepsy	17/242,075			USA
GW Research Limited	Use of cannabidiol in the treatment of epilepsy	17/340,885			USA
GW Research Limited	Pharmaceutical compositions	13/606,742	8,512,767	20/Aug/2013	USA
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	2008-002758			Venezuela
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations cannabinoids in combination with non-cannabinoid	00984-2009			Venezuela
GW Pharma Limited	Chemotherapeutic Agents	00986-2009			Venezuela
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	0001086-2010			Venezuela
GW Pharma Limited	Phytocannabinoids in the treatment of cancer	00294-2011			Venezuela
GW Pharma Limited	CBDV EPILEPSY	00418-2011			Venezuela

Schedule II to
Supplement No. 1 to the
Collateral Agreement

Owner	Title	Application Number	Patent Number	Grant Date	Country
GW Pharma Limited	CBD / SAED'S combination	00008-2012			Venezuela
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	01245-2012			Venezuela
GW Research Limited	Microparticulate formulations	2020-000085			Venezuela
GW Research Limited	CANNABINOID DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF PREPARATION THEREOF	2020-000111			Venezuela
GW Research Limited	Use Of Cannabidiol In The Treatment Of Dravet Syndrome	2020-000114			Venezuela
GW Research Limited	(-)-cis-THC First Medical Use	2020-000180			Venezuela
GW Research Limited	(+)-cis-THC First Medical Use	2020-000182			Venezuela
GW Research Limited	(+)-trans-THC First Medical Use	2020-000181			Venezuela
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020-000201			Venezuela
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020-000202			Venezuela
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020-000203			Venezuela
GW Research Limited	CANNABIDIOL-TYPE CANNABINOID COMPOUND	2020-000200			Venezuela
GW Pharma Limited	Use of cannabinoids in combination with an anti-psychotic medicament	1-2010-01787			Vietnam
GW Pharma Limited	Anti-tumoural effects of cannabinoid combinations	1-2010-03181			Vietnam
GW Pharma Limited	Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy	1-2012-00234			Vietnam
GW Pharma Limited	CBDV EPILEPSY	1-2012-03056			Vietnam
GW Pharma Limited	CBD / SAED'S combination	1-2013-02282			Vietnam
GW Pharma Limited	A PHARMACEUTICAL COMPOSITION COMPRISING THE PHYTOCANNABINOIDS CANNABIDIVARIN (CBDV) AND CANNABIDIOL (CBD)	1-2014-00886			Vietnam

B. **U.S. Federally Registered Copyrights Owned or Exclusively Licensed**

None.

C. U.S. Federally Registered or Applied for Trademarks

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Albania
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Albania
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Albania
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Albania
GW Pharma Limited	SATIVEX in Cyrillic characters	AL/T/2014/256	30 Apr 2014	Albania
GW Pharma Limited	ASCELTA	3819778	15 Jul 2019	Argentina
GW Pharma Limited	GW PHARMACEUTICALS	3761017	26 Nov 2018	Argentina
GW Pharma Limited	GW PHARMACEUTICALS	3761016	26 Nov 2018	Argentina
GW Pharma Limited	GW Pharmaceuticals (Stylised)	3761014	26 Nov 2018	Argentina
GW Pharma Limited	GW Pharmaceuticals (Stylised)	3761015	26 Nov 2018	Argentina
GW Pharma Limited	SATIV	3841012	03 Oct 2019	Argentina
GW Pharma Limited	SATIVEX	2967045	16 Dec 2009	Argentina
GW Research Limited	EPIDYOLEX	3684181	15 Feb 2018	Argentina
GW Research Limited	EPIDYOLEX	3684182	15 Feb 2018	Argentina
GW Research Limited	EPIDIOLEX	3728932	30 Jul 2018	Argentina
GW Research Limited	EPIDIOLEX	3728929	30 Jul 2018	Argentina
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Australia
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Australia
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Australia
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Australia
GW Pharma Limited	GW PHARMA	1830933	09 Mar 2017	Australia
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Australia
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Australia
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Australia
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Australia
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Australia
GW Pharma Limited	WE ARE MORE THAN	2137387	19 Nov 2020	Australia
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Australia
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Australia
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Australia
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Australia
GW Research Limited	Epidyolex Logo (Series of 2)	2001371	05 Apr 2019	Australia
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Australia
GW Research Limited	TETRAVINEX	820250	06 Nov 2003	Australia
GW Research Limited	TETRAVINEX	918111	20 Nov 2006	Australia
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Australia
GW Research Limited	CANNABIDIOL ORAL SOLUTION	AM231/2020	29 Jul 2019	Austria
GW Research Limited	CBD ORAL SOLUTION	AM229/2020	29 Jul 2019	Austria
GW Research Limited	CANNABIDIOL OS	AM230/2020	29 Jul 2019	Austria

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	CBD OS	AM228/2020	29 Jul 2019	Austria
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Bahrain
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Bahrain
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Bahrain
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Bahrain
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Bahrain
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Bahrain
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Bahrain
GW Research Limited	THERACANNEX	1154748	09 Feb 2013	Bahrain
GW Research Limited	CANNABIDIOL ORAL SOLUTION	1413649	29 Jul 2019	Benelux
GW Research Limited	CANNABIDIOL OS	1413643	29 Jul 2019	Benelux
GW Research Limited	CBD ORAL SOLUTION	1413647	29 Jul 2019	Benelux
GW Research Limited	CBD OS	1413635	29 Jul 2019	Benelux
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Bosnia & Herzegovina
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Bosnia & Herzegovina
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Bosnia & Herzegovina
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Bosnia & Herzegovina
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Brazil
GW Pharma Limited	SATIV	918389852	04 Oct 2019	Brazil
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Brazil
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Brazil
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Brazil
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Brazil
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Brazil
GW Pharma Limited	GW PHARMACEUTICALS	916329356	28 Nov 2018	Brazil
GW Pharma Limited	GW Pharmaceuticals (Stylised)	916329313	28 Nov 2018	Brazil
GW Pharma Limited	SATIVEX	830480595	21 Dec 2009	Brazil
GW Pharma Limited	ASCELTA	917758102	18 Jul 2019	Brazil
GW Pharma Limited	GW PHARMACEUTICALS	916329380	28 Nov 2018	Brazil
GW Pharma Limited	GW Pharmaceuticals (Stylised)	916329330	28 Nov 2018	Brazil
GW Pharma Limited	MORE THAN	921402449	24 Nov 2020	Brazil
GW Pharma Limited	MORE THAN	921402759	24 Nov 2020	Brazil

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	WE ARE MORE THAN	921515049	04 Dec 2020	Brazil
GW Pharma Limited	WE ARE MORE THAN	921515383	04 Dec 2020	Brazil
GW Research Limited	EPIDIOLEX	914114077	01 Feb 2018	Brazil
GW Research Limited	EPIDIOLEX	914114107	01 Feb 2018	Brazil
GW Research Limited	EPIDYOLEX	914355880	19 Mar 2018	Brazil
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Brazil
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Brazil
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Brazil
GW Research Limited	EPIDYOLEX	914355694	19 Mar 2018	Brazil
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Bulgaria
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Bulgaria
GW Pharma Limited	SATIVEX in Cyrillic characters	2014132359N	29 Apr 2014	Bulgaria
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Bulgaria
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Bulgaria
GW Research Limited	TETANABINEX	820250	06 Nov 2003	Bulgaria
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Bulgaria
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Canada
GW Pharma Limited	GREENWICH	1414068	24 Apr 2018	Canada
GW Pharma Limited	GW PHARMACEUTICALS	1936407	17 Dec 2018	Canada
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1936408	17 Dec 2018	Canada
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Canada
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Canada
GW Pharma Limited	WE ARE MORE THAN	2093642	22 Mar 2021	Canada
GW Pharma Limited	GW PHARMA	1826311	08 Mar 2017	Canada
GW Pharma Limited	SATIVEX	1163979	06 Jan 2003	Canada
GW Pharma Limited	SATIVEX	1284363	22 Dec 2005	Canada
GW Research Limited	CANNABINEWS	2008256	27 Jan 2020	Canada
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Canada
GW Research Limited	CANNABINOID EDUCATION WORKING GROUP	2009509	03 Feb 2020	Canada
GW Research Limited	CANNABINOIDCLINICAL	2009508	03 Feb 2020	Canada
GW Research Limited	CEWG	2009510	03 Feb 2020	Canada
GW Research Limited	EPIDIOLEX	1818624	18 Jan 2017	Canada
GW Research Limited	EPIDIOLEX	1912786	01 Aug 2018	Canada
GW Research Limited	EPIDYOLEX	1882918	13 Feb 2018	Canada
GW Research Limited	Epidyolex Logo	1928280	01 Nov 2018	Canada
GW Research Limited	NABIDIOLEX	1196173	06 Nov 2003	Canada
GW Research Limited	TETANABINEX	1196172	06 Nov 2003	Canada
GW Pharma Limited	ASCELTA	1330052	17 Jul 2019	Chile
GW Pharma Limited	GW PHARMACEUTICALS	1312256	16 Jan 2019	Chile
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1312260	16 Jan 2019	Chile
GW Pharma Limited	SATIV	1338137	03 Oct 2019	Chile

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	SATIVEX	1133486	28 Nov 2014	Chile
GW Research Limited	EPIDIOLEX	1.295.685	27 Jul 2018	Chile
GW Research Limited	EPIDYOLEX	1281963	08 Mar 2018	Chile
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	China
GW Pharma Limited	GREENWICH	1414068	24 Apr 2018	China
GW Pharma Limited	GREENWICH in English and Chinese characters	52338731	21 Dec 2020	China
GW Pharma Limited	GREENWICH in English and Chinese characters	56111405	17 May 2021	China
GW Pharma Limited	GW PHARMACEUTICALS	37771593	25 Apr 2019	China
GW Pharma Limited	GW PHARMACEUTICALS	37771594	25 Apr 2019	China
GW Pharma Limited	GW PHARMACEUTICALS (Stylised)	37771591	25 Apr 2019	China
GW Pharma Limited	GW PHARMACEUTICALS (Stylised)	37771592	25 Apr 2019	China
GW Pharma Limited	GREENWICH in Chinese characters	48450780	28 Jul 2020	China
GW Pharma Limited	GREENWICH in Chinese characters	48472462	28 Jul 2020	China
GW Pharma Limited	GW PHARMACEUTICALS in Chinese characters	48450798	28 Jul 2020	China
GW Pharma Limited	GW PHARMACEUTICALS in Chinese characters	48472469	28 Jul 2020	China
GW Pharma Limited	SATIV	1508059	03 Oct 2019	China
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	China
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	China
GW Pharma Limited	SATIVEX	47788038	03 Jul 2020	China
GW Pharma Limited	Sativex Design	47799225	03 Jul 2020	China
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	China
GW Pharma Limited	SATIVEX in Chinese characters	48466663	28 Jul 2020	China
GW Pharma Limited	SATIVEX in Chinese characters	48461866	28 Jul 2020	China
GW Research Limited	EPIDYOLEX in Chinese characters	48752733	07 Aug 2020	China
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	China
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	China
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	China
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	China
GW Research Limited	EPIDIOLEX in Chinese characters	48768022	07 Aug 2020	China
GW Research Limited	EPIDIOLEX in Chinese characters	48752724	07 Aug 2020	China
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	China
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	China
GW Research Limited	EPIDYOLEX in Chinese characters	48768031	07 Aug 2020	China
GW Research Limited	Epidyolex Logo	1460321	01 Feb 2019	China
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	China
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	China
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	China
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Colombia
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Colombia
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Colombia
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Colombia

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Colombia
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Colombia
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Colombia
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Colombia
GW Pharma Limited	SATIVEX	09-141935	11 Dec 2009	Colombia
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Colombia
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Colombia
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Colombia
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Colombia
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Colombia
GW Pharma Limited	ASCELTA	2019-6437	17 Jul 2019	Costa Rica
GW Pharma Limited	SATIV	2019-9163	04 Oct 2019	Costa Rica
GW Pharma Limited	SATIVEX	2014-010556	04 Dec 2014	Costa Rica
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Croatia
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Croatia
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Cuba
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Cuba
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Cuba
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Cyprus
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Cyprus
GW Research Limited	TETANABINEX	820250	06 Nov 2003	Cyprus
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Czech Republic
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Czech Republic
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Czech Republic
GW Research Limited	TETANABINEX	820250	06 Nov 2003	Czech Republic
GW Research Limited	CANNABIDIOL OS	VA202000590	29 Jul 2019	Denmark
GW Research Limited	CBD OS	VA202000591	29 Jul 2019	Denmark
GW Research Limited	CANNABIDIOL ORAL SOLUTION	VA202000593	29 Jul 2019	Denmark
GW Research Limited	CBD ORAL SOLUTION	VA202000592	29 Jul 2019	Denmark
GW Pharma Limited	ASCELTA	SENADI-2019-71879	02 Oct 2019	Ecuador
GW Pharma Limited	SATIV	SENADI-2019-72167	03 Oct 2019	Ecuador
GW Pharma Limited	SATIVEX	2014-29270	28 Nov 2014	Ecuador
GW Research Limited	EPIDIOLEX	2018-57058	27 Jul 2018	Ecuador
GW Research Limited	EPIDIOLEX	2018-57061	27 Jul 2018	Ecuador
GW Research Limited	EPIDYOLEX	2018-11117	14 Feb 2018	Ecuador
GW Research Limited	EPIDYOLEX	2018-11113	14 Feb 2018	Ecuador
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Egypt
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Egypt
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Egypt
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Egypt
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Egypt

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	THERACANNEX	1154748	09 Feb 2013	Egypt
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Estonia
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Estonia
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Estonia
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Estonia
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	European Community
GW Pharma Limited	ASCELTA	018016661	29 Jan 2019	European Community
GW Pharma Limited	CANNGESIC	003477312	30 Oct 2003	European Community
GW Pharma Limited	GREENWICH	1414068	24 Apr 2018	European Community
GW Pharma Limited	GREENWICH ANIMAL HEALTH	1415188	24 Apr 2018	European Community
GW Pharma Limited	GREENWICH BIOSCIENCES	016140791	07 Dec 2016	European Community
GW Pharma Limited	GREENWICH BOTANICALS	1413521	24 Apr 2018	European Community
GW Pharma Limited	GW ANIMAL HEALTH	1419348	24 Apr 2018	European Community
GW Pharma Limited	GW BOTANICALS	1414095	24 Apr 2018	European Community
GW Pharma Limited	GW PHARMA	016448201	08 Mar 2017	European Community
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	European Community
GW Pharma Limited	GW Pharmaceuticals (stylised)	003477544	30 Oct 2003	European Community
GW Pharma Limited	GWP	1220878	25 Jun 2014	European Community
GW Pharma Limited	GWPCARE	013172846	14 Aug 2014	European Community
GW Pharma Limited	GWPCARE Logo	013173075	14 Aug 2014	European Community
GW Pharma Limited	GWPHARM	1220677	05 Jun 2014	European Community
GW Pharma Limited	MORE THAN	018189213	29 Jan 2020	European Community
GW Pharma Limited	SATIV	1508059	03 Oct 2019	European Community
GW Pharma Limited	SATIVEX	004800819	22 Dec 2005	European Community
GW Pharma Limited	SATIVEX	002993384	02 Jan 2003	European Community
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	European Community
GW Pharma Limited	CANNABIDEX	002993525	03 Jan 2003	European Community
GW Research Limited	NEODIOLEX	1099312	27 Oct 2011	European Community
GW Research Limited	NEONABIDEX	1099311	27 Oct 2011	European Community
GW Research Limited	QISSIQ	017012899	21 Jul 2017	European Community
GW Research Limited	Cannabinoid Education 360	018292960	18 Aug 2020	European Community
GW Research Limited	ALIGHT	018168689	17 Dec 2019	European Community
GW Research Limited	BEXUB	017012873	21 Jul 2017	European Community
GW Research Limited	CANNABIDIOL ORAL SOLUTION	018100171	29 Jul 2019	European Community
GW Research Limited	CANNABIDIOL OS	018100168	29 Jul 2019	European Community
GW Research Limited	Cannabinoid Education 360 Logo	018292958	18 Aug 2020	European Community
GW Research Limited	CANTIVEX	003477346	30 Oct 2003	European Community
GW Research Limited	CBD ORAL SOLUTION	018100167	29 Jul 2019	European Community
GW Research Limited	CBD OS	018100165	29 Jul 2019	European Community
GW Research Limited	COMBIDIOL	1119094	11 Apr 2012	European Community
GW Research Limited	COMBIDIOLEX	1123182	11 Apr 2012	European Community

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	DUCANNEX	003478054	30 Oct 2003	European Community
GW Research Limited	EJOZY	017012881	21 Jul 2017	European Community
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	European Community
GW Research Limited	EPIDIOLEX	012639373	26 Feb 2014	European Community
GW Research Limited	EPIDYOLEX	016409179	27 Feb 2017	European Community
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	European Community
GW Research Limited	Epidyolex Logo	1460321	01 Feb 2019	European Community
GW Research Limited	EPIVARINEX	1222832	18 Jun 2014	European Community
GW Research Limited	EPYDIOLEX	016409153	27 Feb 2017	European Community
GW Research Limited	FEPURYX	017012725	21 Jul 2017	European Community
GW Research Limited	IABNI	017012824	21 Jul 2017	European Community
GW Research Limited	JESCABE	017012841	21 Jul 2017	European Community
GW Research Limited	NABIDIOLEX	003477353	30 Oct 2003	European Community
GW Research Limited	OPURFY	017012733	21 Jul 2017	European Community
GW Research Limited	ORORA	017017237	21 Jul 2017	European Community
GW Research Limited	PACAMZO	017012782	21 Jul 2017	European Community
GW Research Limited	PEFYO	017012857	21 Jul 2017	European Community
GW Research Limited	SESKYO	017012766	21 Jul 2017	European Community
GW Research Limited	SISLEFIO	017012865	21 Jul 2017	European Community
GW Research Limited	TETRAVINEX	003477387	30 Oct 2003	European Community
GW Research Limited	TETRAVINEX	918111	20 Nov 2006	European Community
GW Research Limited	THEACANNEX	002993764	03 Jan 2003	European Community
GW Research Limited	UCREDLA	017012808	21 Jul 2017	European Community
GW Research Limited	VUCAVY	017012774	21 Jul 2017	European Community
GW Research Limited	XORVEN	017012907	21 Jul 2017	European Community
GW Research Limited	CANNABIDIOL ORAL SOLUTION	T202000016	29 Jul 2019	Finland
GW Research Limited	CANNABIDIOL OS	T202000015	29 Jul 2019	Finland
GW Research Limited	CBD ORAL SOLUTION	T202000014	29 Jul 2019	Finland
GW Research Limited	CBD OS	T202000013	29 Jul 2019	Finland
GW Pharma Limited	GW PHARMA	305347233	30 Jul 2020	Hong Kong
GW Pharma Limited	GW PHARMACEUTICALS	305347224	30 Jul 2020	Hong Kong
GW Pharma Limited	GW PHARMACEUTICALS (stylised)	305347251	30 Jul 2020	Hong Kong
GW Pharma Limited	GWPHARM	305347242	30 Jul 2020	Hong Kong
GW Research Limited	EPIDIOLEX	305271714	13 May 2020	Hong Kong
GW Research Limited	EPIDYOLEX	305271723	13 May 2020	Hong Kong
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Hungary
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Hungary
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Hungary
GW Research Limited	TETRAVINEX	820250	06 Nov 2003	Hungary
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Iceland
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Iceland

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Iceland
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Iceland
GW Pharma Limited	SATIV	1508059	03 Oct 2019	India
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	India
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	India
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	India
GW Pharma Limited	GW Pharmaceuticals (stylised)	1262692	22 Jan 2004	India
GW Pharma Limited	SATIVEX	1216859	23 Jul 2003	India
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	India
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	India
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	India
GW Research Limited	NABIDIOLEX	1248283	07 Nov 2003	India
GW Research Limited	TETRA V ARINEX	1506906	23 Nov 2006	India
GW Research Limited	TETRANABINEX	1248282	07 Nov 2003	India
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Indonesia
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Indonesia
GW Pharma Limited	SATIVEX	D002010003768	01 Feb 2010	Indonesia
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Israel
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Israel
GW Pharma Limited	MORE THAN	333741	25 Nov 2020	Israel
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Israel
GW Pharma Limited	WE ARE MORE THAN	333740	25 Nov 2020	Israel
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Israel
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Israel
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Israel
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Israel
GW Pharma Limited	SATIVEX	162116	05 Jan 2003	Israel
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Israel
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Israel
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Israel
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Israel
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Israel
GW Research Limited	Epidyolex Logo	315633	07 Apr 2019	Israel
GW Research Limited	NABIDIOLEX	167829	06 Nov 2003	Israel
GW Research Limited	TETRANABINEX	167830	06 Nov 2003	Israel
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Japan
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Japan
GW Pharma Limited	MORE THAN	2020-145225	25 Nov 2020	Japan
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Japan
GW Pharma Limited	WE ARE MORE THAN	2020-145224	25 Nov 2020	Japan
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Japan

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Japan
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Japan
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Japan
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Japan
GW Research Limited	NEODIOLEX	1099312	27 Oct 2011	Japan
GW Research Limited	NEONABIDEX	1099311	27 Oct 2011	Japan
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Japan
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Japan
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Japan
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Japan
GW Research Limited	NEODIOL	1099310	27 Oct 2011	Japan
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Japan
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Japan
GW Pharma Limited	ASCELTA	KS/M/2019/000955	16 Jul 2019	Kosovo
GW Pharma Limited	SATIV	KS/M/2019/001283	04 Oct 2019	Kosovo
GW Pharma Limited	SATIVEX	KS/M/2014/395	30 Apr 2014	Kosovo
GW Pharma Limited	Sativex Design	KS/M/2014/394	30 Apr 2014	Kosovo
GW Pharma Limited	SATIVEX in Cyrillic characters	KS/M/2014/393	30 Apr 2014	Kosovo
GW Pharma Limited	ASCELTA	2019/007335	05 Sep 2019	Kuwait
GW Pharma Limited	SATIV	2019/008276	06 Oct 2019	Kuwait
GW Pharma Limited	SATIVEX	134770	18 Nov 2012	Kuwait
GW Research Limited	CANTIVEX	134769	18 Nov 2012	Kuwait
GW Research Limited	THERACANNEX	137289	11 Feb 2013	Kuwait
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Latvia
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Latvia
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Latvia
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Latvia
GW Research Limited	EPIDIOLEX	198372	22 Sep 2020	Lebanon
GW Research Limited	EPIDYOLEX	198373	22 Sep 2020	Lebanon
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Liechtenstein
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Liechtenstein
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Liechtenstein
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Liechtenstein
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Liechtenstein
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Liechtenstein
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Lithuania
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Lithuania
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Lithuania
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Lithuania
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Madrid Protocol (TM)
GW Pharma Limited	GREENWICH	1414068	24 Apr 2018	Madrid Protocol (TM)

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	GREENWICH ANIMAL HEALTH	1415188	24 Apr 2018	Madrid Protocol (TM)
GW Pharma Limited	GREENWICH BOTANICALS	1413521	24 Apr 2018	Madrid Protocol (TM)
GW Pharma Limited	GW ANIMAL HEALTH	1419348	24 Apr 2018	Madrid Protocol (TM)
GW Pharma Limited	GW BOTANICALS	1414095	24 Apr 2018	Madrid Protocol (TM)
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Madrid Protocol (TM)
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Madrid Protocol (TM)
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Madrid Protocol (TM)
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Madrid Protocol (TM)
GW Pharma Limited	GWP	1220878	25 Jun 2014	Madrid Protocol (TM)
GW Pharma Limited	GWPHARM	1220677	05 Jun 2014	Madrid Protocol (TM)
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Madrid Protocol (TM)
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Madrid Protocol (TM)
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Madrid Protocol (TM)
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Madrid Protocol (TM)
GW Research Limited	NEODIOLEX	1099312	27 Oct 2011	Madrid Protocol (TM)
GW Research Limited	NEONABIDEX	1099311	27 Oct 2011	Madrid Protocol (TM)
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Madrid Protocol (TM)
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Madrid Protocol (TM)
GW Research Limited	COMBIDIOL	1119094	11 Apr 2012	Madrid Protocol (TM)
GW Research Limited	COMBIDIOLEX	1123182	11 Apr 2012	Madrid Protocol (TM)
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Madrid Protocol (TM)
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Madrid Protocol (TM)
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Madrid Protocol (TM)
GW Research Limited	Epidyolex Logo	1460321	01 Feb 2019	Madrid Protocol (TM)
GW Research Limited	EPIVARINEX	1222832	18 Jun 2014	Madrid Protocol (TM)
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Madrid Protocol (TM)
GW Research Limited	NEODIOL	1099310	27 Oct 2011	Madrid Protocol (TM)
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Madrid Protocol (TM)
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Madrid Protocol (TM)
GW Research Limited	THERACANNEX	1154748	09 Feb 2013	Madrid Protocol (TM)
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Mexico
GW Pharma Limited	SATIVEX	1062113	22 Jan 2010	Mexico
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Mexico
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Mexico

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Mexico
GW Pharma Limited	MORE THAN	2458263	24 Nov 2020	Mexico
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Mexico
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Mexico
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Mexico
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Mexico
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Mexico
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Mexico
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Mexico
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Mexico
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Mexico
GW Pharma Limited	MORE THAN	2458261	24 Nov 2020	Mexico
GW Pharma Limited	SATIVEX	2319594	22 Jan 2020	Mexico
GW Pharma Limited	Sativex Design	1262255	29 Mar 2012	Mexico
GW Pharma Limited	WE ARE MORE THAN	2458268	24 Nov 2020	Mexico
GW Pharma Limited	WE ARE MORE THAN	2458264	24 Nov 2020	Mexico
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Mexico
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Mexico
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Mexico
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Mexico
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Mexico
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Mexico
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Mexico
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Montenegro
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Montenegro
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Montenegro
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Montenegro
GW Pharma Limited	SATIVEX in Cyrillic characters	Z-2014-178	30 Apr 2014	Montenegro
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	New Zealand
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	New Zealand
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	New Zealand
GW Pharma Limited	GW Pharmaceuticals (stylised)	707134	21 Jan 2004	New Zealand
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	New Zealand
GW Pharma Limited	SATIV	1508059	03 Oct 2019	New Zealand
GW Pharma Limited	SATIVEX	678744	21 May 2003	New Zealand
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	New Zealand
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	New Zealand
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	New Zealand
GW Research Limited	Epidyolex Logo (Series of 2)	1117930	05 Apr 2019	New Zealand
GW Research Limited	NABIDIOLEX	704224	19 Nov 2003	New Zealand

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	TETANABINEX	704223	10 Nov 2003	New Zealand
GW Pharma Limited	GW PHARMA	202009637	30 Jul 2020	Norway
GW Pharma Limited	GW PHARMACEUTICALS	202009635	30 Jul 2020	Norway
GW Pharma Limited	GW PHARMACEUTICALS (stylised)	202009639	30 Jul 2020	Norway
GW Pharma Limited	GWPHARM	202009638	30 Jul 2020	Norway
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Norway
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Norway
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Norway
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Norway
GW Research Limited	CANNABIDIOL ORAL SOLUTION	202003054	28 Feb 2020	Norway
GW Research Limited	CANNABIDIOL OS	202003053	28 Feb 2020	Norway
GW Research Limited	CBD ORAL SOLUTION	202003052	28 Feb 2020	Norway
GW Research Limited	CBD OS	202003051	28 Feb 2020	Norway
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Norway
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Norway
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Norway
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Norway
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Norway
GW Research Limited	TETANABINEX	820250	06 Nov 2003	Norway
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Norway
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Oman
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Oman
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Oman
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Oman
GW Research Limited	THERACANNEX	1154748	09 Feb 2013	Oman
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Oman
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Oman
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Oman
GW Pharma Limited	ASCELTA	275039-01	18 Jul 2019	Panama
GW Pharma Limited	SATIV	276978-01	04 Oct 2019	Panama
GW Pharma Limited	SATIVEX	236894	02 Dec 2014	Panama
GW Research Limited	EPIDIOLEX	267710-01	01 Aug 2018	Panama
GW Research Limited	EPIDYOLEX	264147-01	19 Feb 2018	Panama
GW Pharma Limited	ASCELTA	58557-19	19 Jul 2019	Paraguay
GW Pharma Limited	SATIV	83220/19	04 Oct 2019	Paraguay
GW Pharma Limited	SATIVEX	2174 /2015	27 Jan 2015	Paraguay
GW Research Limited	EPIDIOLEX	63078-18	01 Aug 2018	Paraguay
GW Research Limited	EPIDIOLEX	63081-18	01 Aug 2018	Paraguay
GW Research Limited	EPIDYOLEX	1809957	16 Feb 2018	Paraguay
GW Research Limited	EPIDYOLEX	1809956	16 Feb 2018	Paraguay
GW Pharma Limited	ASCELTA	806897-2019	17 Jul 2019	Peru

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	SATIV	820484	04 Oct 2019	Peru
GW Pharma Limited	SATIVEX	771683-2018	25 Oct 2018	Peru
GW Research Limited	EPIDIOLEX	760008	31 Jul 2018	Peru
GW Research Limited	EPIDYOLEX	738459	16 Feb 2018	Peru
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Poland
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Poland
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Poland
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Poland
GW Research Limited	EPIDYOLEX	225161-31-0	14 Feb 2018	Puerto Rico
GW Research Limited	EPIDYOLEX	225160-05-0	14 Feb 2018	Puerto Rico
GW Research Limited	EPIDIOLEX	227938-05-0	30 Jul 2018	Puerto Rico
GW Research Limited	EPIDIOLEX	227939-31-0	30 Jul 2018	Puerto Rico
GW Research Limited	EPIDYOLEX	244362-05-0	22 Jun 2021	Puerto Rico
GW Pharma Limited	SATIV	134830	02 Oct 2019	Qatar
GW Pharma Limited	SATIVEX	77783	12 Nov 2012	Qatar
GW Pharma Limited	ASCELT A	133861	22 Aug 2019	Qatar
GW Research Limited	CANTIVEX	77784	12 Nov 2012	Qatar
GW Research Limited	THERACANNEX	79508	10 Feb 2013	Qatar
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Republic of Korea
GW Pharma Limited	GW PHARMA	1594926	29 Jan 2021	Republic of Korea
GW Pharma Limited	GW PHARMACEUTICALS	1593385	29 Jan 2021	Republic of Korea
GW Pharma Limited	MORE THAN	40-2020-0217324	30 Nov 2020	Republic of Korea
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Republic of Korea
GW Pharma Limited	WE ARE MORE THAN	40-2020-0217323	30 Nov 2020	Republic of Korea
GW Pharma Limited	ASCELT A	1484201	12 Jul 2019	Republic of Korea
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Republic of Korea
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Republic of Korea
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Republic of Korea
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Republic of Korea
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Republic of Korea
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Republic of Korea
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Republic of Korea
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Republic of Korea
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Romania
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Romania
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Romania
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Romania
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Romania
GW Pharma Limited	ASCELT A	1484201	12 Jul 2019	Russian Federation
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Russian Federation
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Russian Federation

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	ASCELTA	195436	31 Jul 2019	Saudi Arabia
GW Pharma Limited	GW PHARMACEUTICALS	170853	15 Jan 2019	Saudi Arabia
GW Pharma Limited	GW PHARMACEUTICALS	170855	15 Jan 2019	Saudi Arabia
GW Pharma Limited	GW Pharmaceuticals (Stylised)	170899	16 Jan 2019	Saudi Arabia
GW Pharma Limited	GW Pharmaceuticals (Stylised)	170901	16 Jan 2019	Saudi Arabia
GW Pharma Limited	SATIV	202454	06 Oct 2019	Saudi Arabia
GW Pharma Limited	SATIVEX	162129	30 Nov 2010	Saudi Arabia
GW Research Limited	CANTIVEX	187477	17 Oct 2012	Saudi Arabia
GW Research Limited	EPIDIOLEX	239234	03 Sep 2020	Saudi Arabia
GW Research Limited	EPIDIOLEX	239236	03 Sep 2020	Saudi Arabia
GW Research Limited	EPIDYOLEX	239238	03 Sep 2020	Saudi Arabia
GW Research Limited	EPIDYOLEX	239242	03 Sep 2020	Saudi Arabia
GW Research Limited	THERACANNEX	192148	11 Feb 2013	Saudi Arabia
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Serbia
GW Pharma Limited	GW PHARMA	Z-1284/2020	30 Jul 2020	Serbia
GW Pharma Limited	GW PHARMACEUTICALS	Z-1283/2020	30 Jul 2020	Serbia
GW Pharma Limited	GW PHARMACEUTICALS (stylised)	Z-1286/2020	30 Jul 2020	Serbia
GW Pharma Limited	GWPHARM	Z-1285/2020	30 Jul 2020	Serbia
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Serbia
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Serbia
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Serbia
GW Pharma Limited	SATIVEX in Cyrillic characters	Z-2014-0641	30 Apr 2014	Serbia
GW Research Limited	ALIGHT	Z-2005/2019	17 Dec 2019	Serbia
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Serbia
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Serbia
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Serbia
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Serbia
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Serbia
GW Research Limited	TETRAANABINEX	820250	06 Nov 2003	Serbia
GW Pharma Limited	GW PHARMA	40202016090Y	03 Aug 2020	Singapore
GW Pharma Limited	GW PHARMACEUTICALS	40202016089W	03 Aug 2020	Singapore
GW Pharma Limited	GW PHARMACEUTICALS (stylised)	40202016091T	03 Aug 2020	Singapore
GW Pharma Limited	GWPHARM	40202016092S	03 Aug 2020	Singapore
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Singapore
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Singapore
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Singapore
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Singapore
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Singapore
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Singapore
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Singapore
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Singapore

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Singapore
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Slovakia
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Slovakia
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Slovakia
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Slovakia
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Slovenia
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Slovenia
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Slovenia
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Slovenia
GW Pharma Limited	ASCELTA	2019/19694	16 Jul 2019	South Africa
GW Pharma Limited	SATIV	2019/28183	04 Oct 2019	South Africa
GW Pharma Limited	SATIVEX	2009/25333	10 Dec 2009	South Africa
GW Pharma Limited	GW PHARMACEUTICALS	2018/35260	26 Nov 2018	South Africa
GW Pharma Limited	GW PHARMACEUTICALS	2018/35259	26 Nov 2018	South Africa
GW Pharma Limited	GW Pharmaceuticals (Stylised)	2018/35258	26 Nov 2018	South Africa
GW Pharma Limited	GW Pharmaceuticals (Stylised)	2018/35257	26 Nov 2018	South Africa
GW Research Limited	EPIDYOLEX	2019/27594	27 Sep 2019	South Africa
GW Research Limited	EPIDYOLEX	2019/27591	27 Sep 2019	South Africa
GW Research Limited	EPIDIOLEX	2019/27592	27 Sep 2019	South Africa
GW Research Limited	EPIDIOLEX	2019/27593	27 Sep 2019	South Africa
GW Pharma Limited	Sativex design	2903919	03 Dec 2009	Spain
GW Research Limited	CANNABIDIOL ORAL SOLUTION	2020/01966	17 Mar 2020	Sweden
GW Research Limited	CANNABIDIOL OS	2020/01971	17 Mar 2020	Sweden
GW Research Limited	CBD ORAL SOLUTION	2020/01968	17 Mar 2020	Sweden
GW Research Limited	CBD OS	2020/01974	17 Mar 2020	Sweden
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Switzerland
GW Pharma Limited	GW PHARMA	10710/2020	30 Jul 2020	Switzerland
GW Pharma Limited	GW PHARMACEUTICALS	10707/2020	30 Jul 2020	Switzerland
GW Pharma Limited	GW PHARMACEUTICALS (stylised)	10716/2020	30 Jul 2020	Switzerland
GW Pharma Limited	GWPHARM	10714/2020	30 Jul 2020	Switzerland
GW Pharma Limited	SATIVEX	1594371	29 Jan 2021	Switzerland
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Switzerland
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Switzerland
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Switzerland
GW Research Limited	CANNABIDIOL ORAL SOLUTION	02781/2020	28 Feb 2020	Switzerland
GW Research Limited	Cannabinoid Education 360 (Device)	1586002	17 Feb 2021	Switzerland
GW Research Limited	CBD ORAL SOLUTION	02780/2020	28 Feb 2020	Switzerland
GW Research Limited	CANNABIDIOL OS	02783/2020	28 Feb 2020	Switzerland
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Switzerland
GW Research Limited	CBD OS	02778/2020	28 Feb 2020	Switzerland
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Switzerland

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Switzerland
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Switzerland
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Switzerland
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Switzerland
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Switzerland
GW Pharma Limited	GW PHARMA	110001705	08 Jan 2021	Taiwan
GW Pharma Limited	GW PHARMACEUTICALS	110002772	14 Jan 2021	Taiwan
GW Pharma Limited	GWPHARM	110001706	08 Jan 2021	Taiwan
GW Pharma Limited	SATIVEX	110000496	05 Jan 2021	Taiwan
GW Pharma Limited	ASCELTA	108046924	19 Jul 2019	Taiwan
GW Pharma Limited	GW PHARMACEUTICALS	107083126	24 Dec 2018	Taiwan
GW Pharma Limited	GW Pharmaceuticals (Stylised)	107083125	24 Dec 2018	Taiwan
GW Pharma Limited	SATIV	108065428	04 Oct 2019	Taiwan
GW Pharma Limited	SATIVEX	99000643	07 Jan 2010	Taiwan
GW Research Limited	Cannabinoid Education 360 (Device)	110010378	17 Feb 2021	Taiwan
GW Research Limited	EPIDIOLEX	110044656	24 Jun 2021	Taiwan
GW Research Limited	EPIDIOLEX in traditional Chinese characters	110026695	16 Apr 2021	Taiwan
GW Research Limited	EPIDYOLEX	110044657	24 Jun 2021	Taiwan
GW Research Limited	EPIDYOLEX in traditional Chinese characters	110026694	16 Apr 2021	Taiwan
GW Research Limited	EPIDIOLEX	108016022	18 Mar 2019	Taiwan
GW Research Limited	EPIDYOLEX	108016023	18 Mar 2019	Taiwan
GW Pharma Limited	SATIV	1508059	03 Oct 2019	Turkey
GW Pharma Limited	ASCELTA	1484201	12 Jul 2019	Turkey
GW Pharma Limited	GW PHARMACEUTICALS	1459268	28 Feb 2019	Turkey
GW Pharma Limited	GW Pharmaceuticals (Stylised)	1462420	28 Feb 2019	Turkey
GW Pharma Limited	SATIVEX	805396	03 Jan 2003	Turkey
GW Pharma Limited	Sativex Design	1029836	17 Dec 2009	Turkey
GW Research Limited	CANTIVEX	824459	20 Jan 2004	Turkey
GW Research Limited	EPIDIOLEX	1208519	18 Mar 2014	Turkey
GW Research Limited	EPIDIOLEX	1226800	14 Aug 2014	Turkey
GW Research Limited	EPIDYOLEX	1421965	18 Jul 2018	Turkey
GW Research Limited	NABIDIOLEX	816176	06 Nov 2003	Turkey
GW Research Limited	TETTRANABINEX	820250	06 Nov 2003	Turkey
GW Research Limited	TETRAVARINEX	918111	20 Nov 2006	Turkey
GW Pharma Limited	ASCELTA	313991	17 Jul 2019	United Arab Emirates
GW Pharma Limited	CANTIVEX	181113	24 Oct 2012	United Arab Emirates
GW Pharma Limited	GW PHARMACEUTICALS	305768	05 Feb 2019	United Arab Emirates
GW Pharma Limited	GW PHARMACEUTICALS	305769	05 Feb 2019	United Arab Emirates
GW Pharma Limited	GW Pharmaceuticals (Stylised)	305766	05 Feb 2019	United Arab Emirates
GW Pharma Limited	GW Pharmaceuticals (Stylised)	305767	05 Feb 2019	United Arab Emirates
GW Pharma Limited	SATIV	318407	06 Oct 2019	United Arab Emirates

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	SATIVEX	181114	24 Oct 2012	United Arab Emirates
GW Pharma Limited	THERACANNEX	186707	12 Feb 2013	United Arab Emirates
GW Research Limited	EPIDIOLEX	334152	18 Aug 2020	United Arab Emirates
GW Research Limited	EPIDIOLEX	334153	18 Aug 2020	United Arab Emirates
GW Research Limited	EPIDYOLEX	334157	18 Aug 2020	United Arab Emirates
GW Research Limited	EPIDYOLEX	334155	18 Aug 2020	United Arab Emirates
GW Pharma Limited	ASCELTA	UK00003153773	08 Mar 2016	United Kingdom
GW Pharma Limited	ASCELTA	UK00918016661	29 Jan 2019	United Kingdom
GW Pharma Limited	CANNGESIC	2304385	04 Jul 2002	United Kingdom
GW Pharma Limited	CANNGESIC	UK00903477312	30 Oct 2003	United Kingdom
GW Pharma Limited	CEBEDEX	3009946	13 Jun 2013	United Kingdom
GW Pharma Limited	GREENWICH	3272959	24 Nov 2017	United Kingdom
GW Pharma Limited	GREENWICH	UK00801414068	24 Apr 2018	United Kingdom
GW Pharma Limited	GREENWICH ANIMAL HEALTH	3272956	24 Nov 2017	United Kingdom
GW Pharma Limited	GREENWICH ANIMAL HEALTH	UK00801415188	24 Apr 2018	United Kingdom
GW Pharma Limited	GREENWICH BIOSCIENCES	UK00916140791	07 Dec 2016	United Kingdom
GW Pharma Limited	GREENWICH BOTANICALS	3272954	24 Nov 2017	United Kingdom
GW Pharma Limited	GREENWICH BOTANICALS	UK00801413521	24 Apr 2018	United Kingdom
GW Pharma Limited	GW ANIMAL HEALTH	UK00801419348	24 Apr 2018	United Kingdom
GW Pharma Limited	GW ANIMAL HEALTH	3272953	24 Nov 2017	United Kingdom
GW Pharma Limited	GW BOTANICALS	3272949	24 Nov 2017	United Kingdom
GW Pharma Limited	GW BOTANICALS	UK00801414095	24 Apr 2018	United Kingdom
GW Pharma Limited	GW PHARMA	UK00003573451	30 Dec 2020	United Kingdom
GW Pharma Limited	GW PHARMA	UK00916448201	08 Mar 2017	United Kingdom
GW Pharma Limited	GW PHARMACEUTICALS	UK00801459268	28 Feb 2019	United Kingdom
GW Pharma Limited	GW PHARMACEUTICALS	3355223	21 Nov 2018	United Kingdom
GW Pharma Limited	GW Pharmaceuticals (Stylised)	3355228	21 Nov 2018	United Kingdom
GW Pharma Limited	GW Pharmaceuticals (stylised)	UK00903477544	30 Oct 2003	United Kingdom
GW Pharma Limited	GWP	UK00801220878	25 Jun 2014	United Kingdom
GW Pharma Limited	GWP	3038719	21 Jan 2014	United Kingdom
GW Pharma Limited	GWPCARE	UK00913172846	14 Aug 2014	United Kingdom
GW Pharma Limited	GWPCARE	3068493	13 Aug 2014	United Kingdom
GW Pharma Limited	GWPCARE Logo	UK00913173075	14 Aug 2014	United Kingdom
GW Pharma Limited	GWPCARE Logo (Series of 2)	3068496	13 Aug 2014	United Kingdom
GW Pharma Limited	GWPHARM	UK00003573447	30 Dec 2020	United Kingdom
GW Pharma Limited	GWPHARM	UK00801220677	05 Jun 2014	United Kingdom
GW Pharma Limited	GWPHARM	3038722	21 Jan 2014	United Kingdom
GW Pharma Limited	GWPHARM.COM	3038725	21 Jan 2014	United Kingdom
GW Pharma Limited	MEDEXEL	2304391	04 Jul 2002	United Kingdom
GW Pharma Limited	MEDICANNOID	2304384	04 Jul 2002	United Kingdom
GW Pharma Limited	MORE THAN	UK00918189213	29 Jan 2020	United Kingdom

Owner	Mark Name	Application Number	Application Date	Country
GW Pharma Limited	SATIV	3389714	04 Apr 2019	United Kingdom
GW Pharma Limited	SATIV	UK00801508059	03 Oct 2019	United Kingdom
GW Pharma Limited	SATIVECS	2655592	11 Mar 2013	United Kingdom
GW Pharma Limited	SATIVEX	2304388	04 Jul 2002	United Kingdom
GW Pharma Limited	SATIVEX	UK00904800819	22 Dec 2005	United Kingdom
GW Pharma Limited	SATIVEX	2395506	29 Jun 2005	United Kingdom
GW Pharma Limited	SATIVEX	UK00902993384	02 Jan 2003	United Kingdom
GW Pharma Limited	SATIVEX	UK00003573455	30 Dec 2020	United Kingdom
GW Pharma Limited	Sativex Design	UK00801029836	17 Dec 2009	United Kingdom
GW Pharma Limited	UK Medicinal Cannabis Project (Device)	2213257	03 Nov 1999	United Kingdom
GW Pharma Limited	VAPAHALE	2304393	04 Jul 2002	United Kingdom
GW Pharma Limited	VARINEX	2411358	18 Jan 2006	United Kingdom
GW Pharma Limited	ZATIVIX	2655593	11 Mar 2013	United Kingdom
GW Pharma Limited	ZATTIVEX	2655590	11 Mar 2013	United Kingdom
GW Pharma Limited	ZYTIVEX	2655587	11 Mar 2013	United Kingdom
GW Pharma Limited	GW PHARMACEUTICALS	UK00003573453	30 Dec 2020	United Kingdom
GW Research Limited	QISSIQ	3264776	19 Oct 2017	United Kingdom
GW Research Limited	ALIGHT	UK00918168689	17 Dec 2019	United Kingdom
GW Research Limited	BEXUB	UK00917012873	21 Jul 2017	United Kingdom
GW Research Limited	BICANNEX	2304383	04 Jul 2002	United Kingdom
GW Research Limited	CANNABIDEX	2304389	04 Jul 2002	United Kingdom
GW Research Limited	CANNABIDIOL ORAL SOLUTION	UK00918100171	29 Jul 2019	United Kingdom
GW Research Limited	CANNABIDIOL OS	UK00918100168	29 Jul 2019	United Kingdom
GW Research Limited	Cannabinoid Education 360	UK00003523530	17 Aug 2020	United Kingdom
GW Research Limited	Cannabinoid Education 360 (Series of 2)	UK00003523527	17 Aug 2020	United Kingdom
GW Research Limited	CANNABINOID RESEARCH INSTITUTE	2304395	04 Jul 2002	United Kingdom
GW Research Limited	CANNAVAR	2304386	04 Jul 2002	United Kingdom
GW Research Limited	CANNIVEX	2338253	21 Jul 2003	United Kingdom
GW Research Limited	CANTIVEX	2338259	21 Jul 2003	United Kingdom
GW Research Limited	CANTIVEX	UK00903477346	30 Oct 2003	United Kingdom
GW Research Limited	CBD ORAL SOLUTION	UK00918100167	29 Jul 2019	United Kingdom
GW Research Limited	CBD OS	UK00918100165	29 Jul 2019	United Kingdom
GW Research Limited	CEPAEDEX	3009941	13 Jun 2013	United Kingdom
GW Research Limited	COMBIDIOL	2598672	21 Oct 2011	United Kingdom
GW Research Limited	COMBIDIOL	UK00801119094	11 Apr 2012	United Kingdom
GW Research Limited	COMBIDIOLEX	2598673	21 Oct 2011	United Kingdom
GW Research Limited	COMBIDIOLEX	UK00801123182	11 Apr 2012	United Kingdom
GW Research Limited	CRI	3274822	04 Dec 2017	United Kingdom
GW Research Limited	DUCANNEX	UK00903478054	30 Oct 2003	United Kingdom
GW Research Limited	DUCANNEX	2304387	04 Jul 2002	United Kingdom
GW Research Limited	EJOZY	UK00917012881	21 Jul 2017	United Kingdom

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	EMESCAN	2304392	04 Jul 2002	United Kingdom
GW Research Limited	EPIDIOLEX	UK00003573458	30 Dec 2020	United Kingdom
GW Research Limited	EPIDIOLEX	UK00912639373	26 Feb 2014	United Kingdom
GW Research Limited	EPIDIOLEX	UK00801226800	14 Aug 2014	United Kingdom
GW Research Limited	EPIDIOLEX	3013236	09 Jul 2013	United Kingdom
GW Research Limited	EPIDIOLEX	3068471	13 Aug 2014	United Kingdom
GW Research Limited	EPIDYOLEX	UK00801421965	18 Jul 2018	United Kingdom
GW Research Limited	EPIDYOLEX	3289185	09 Feb 2018	United Kingdom
GW Research Limited	EPIDYOLEX	UK00003573459	30 Dec 2020	United Kingdom
GW Research Limited	EPIDYOLEX	UK00916409179	27 Feb 2017	United Kingdom
GW Research Limited	Epidyolex Logo	UK00801460321	01 Feb 2019	United Kingdom
GW Research Limited	Epidyolex Logo (Series of 2)	3348532	25 Oct 2018	United Kingdom
GW Research Limited	EPINUKIA	3153774	08 Mar 2016	United Kingdom
GW Research Limited	EPIVARINEX	3044567	28 Feb 2014	United Kingdom
GW Research Limited	EPIVARINEX	UK00801222832	18 Jun 2014	United Kingdom
GW Research Limited	EPYDIOLEX	UK00916409153	27 Feb 2017	United Kingdom
GW Research Limited	FEPUYX	UK00917012725	21 Jul 2017	United Kingdom
GW Research Limited	IABNI	UK00917012824	21 Jul 2017	United Kingdom
GW Research Limited	JBSCABE	UK00917012841	21 Jul 2017	United Kingdom
GW Research Limited	KATEULIA	3153780	08 Mar 2016	United Kingdom
GW Research Limited	KYNEUBIA	3153763	08 Mar 2016	United Kingdom
GW Research Limited	KYTEUVIA	3153778	08 Mar 2016	United Kingdom
GW Research Limited	NABIDIOLEX	2331741	08 May 2003	United Kingdom
GW Research Limited	NABIDIOLEX	UK00903477353	30 Oct 2003	United Kingdom
GW Research Limited	NEODIOL	2581189	13 May 2011	United Kingdom
GW Research Limited	NEODIOLEX	2581191	13 May 2011	United Kingdom
GW Research Limited	NEONABIDEX	2581192	13 May 2011	United Kingdom
GW Research Limited	OPURFY	UK00917012733	21 Jul 2017	United Kingdom
GW Research Limited	ORORA	UK00917017237	21 Jul 2017	United Kingdom
GW Research Limited	PACAMZO	UK00917012782	21 Jul 2017	United Kingdom
GW Research Limited	PEFYO	UK00917012857	21 Jul 2017	United Kingdom
GW Research Limited	SATORIVEX	2655595	11 Mar 2013	United Kingdom
GW Research Limited	SESKYO	UK00917012766	21 Jul 2017	United Kingdom
GW Research Limited	SESKYO	3264780	19 Oct 2017	United Kingdom
GW Research Limited	SISLEFIO	UK00917012865	21 Jul 2017	United Kingdom
GW Research Limited	TETTRANABINEX	2331742	08 May 2003	United Kingdom
GW Research Limited	TETTRANABINEX	UK00903477387	30 Oct 2003	United Kingdom
GW Research Limited	TETRAVARINEX	UK00800918111	20 Nov 2006	United Kingdom
GW Research Limited	TETRAVARINEX	2422557	23 May 2006	United Kingdom
GW Research Limited	THERACANNEX	2304371	04 Jul 2002	United Kingdom
GW Research Limited	THERACANNEX	UK00902993764	03 Jan 2003	United Kingdom

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	THERACANNOID	2304390	04 Jul 2002	United Kingdom
GW Research Limited	THERACANNOL	2304373	04 Jul 2002	United Kingdom
GW Research Limited	UCREDLA	UK00917012808	21 Jul 2017	United Kingdom
GW Research Limited	VUCAVY	UK00917012774	21 Jul 2017	United Kingdom
GW Research Limited	XORVEN	UK00917012907	21 Jul 2017	United Kingdom
GW Research Limited	Cannabinoid Education 360	UK00918292960	18 Aug 2020	United Kingdom
GW Research Limited	Cannabinoid Education 360 Logo	UK00918292958	18 Aug 2020	United Kingdom
GW Pharma Limited	GW ANIMAL HEALTH	79239288 IRN: 1419348 (Abandoned)	24 Apr 2018	USA
GW Pharma Limited	GW BOTANICALS	79237068 IRN: 1414095 (Abandoned)	24 Apr 2018	USA
GW Pharma Limited	SATIV	79276064 IRN: 1508059	03 Oct 2019	USA
GW Pharma Limited	SATIVEX	79266020 IRN: 0805396	03 Jan 2003	USA
GW Pharma Limited	GREENWICH	79237055 IRN: 1414068	24 Apr 2018	USA
GW Pharma Limited	GREENWICH ANIMAL HEALTH	79237541 IRN: 1415188	24 Apr 2018	USA
GW Pharma Limited	GREENWICH BOTANICALS	79236872 IRN: 1413521	24 Apr 2018	USA
GW Research Limited	COMBIDIOL	79114028 IRN: 1119094 (Cancelled)	11 Apr 2012	USA
GW Research Limited	COMBIDIOLEX	79115578 IRN: 1123182 (Cancelled)	11 Apr 2012	USA
GW Research Limited	GREENWICH BIOSCIENCES	87/975011 (Abandoned)	26 May 2016	USA
GW Research Limited	NEODIOL	79106176 IRN: 1099310 (Cancelled)	27 Oct 2011	USA
GW Research Limited	NEODIOLEX	79106178 IRN: 1099312 (Cancelled)	27 Oct 2011	USA
GW Research Limited	NEONABIDEX	79106177 IRN: 1099311 (Cancelled)	27 Oct 2011	USA
GW Research Limited	Cannabinoid Education 360 (Device)	79308686 IRN: 1586002	17 Feb 2021	USA

Owner	Mark Name	Application Number	Application Date	Country
GW Research Limited	EPIDIOLEX	79156538 IRN: 1226800	14 Aug 2014	USA
GW Research Limited	EPIDYOLEX	79240362 IRN: 1421965	18 Jul 2018	USA
GW Research Limited	Epidyolex Logo	79256173 IRN: 1460321	01 Feb 2019	USA
GW Research Limited	NABIDIOLEX	85/380134 (Cancelled)	25 Jul 2011	USA
GW Research Limited	TETTRANABINEX	85/380022 (Cancelled)	25 Jul 2011	USA
GW Research Limited	TETRAVARINEX	79036245 IRN: 0918111 (Cancelled)	20 Nov 2006	USA
GW Pharma Limited	GREENWICH BIOSCIENCES	87/979127	26 May 2016	USA
GW Pharma Limited	GREENWICH BIOSCIENCES	87/977676	26 May 2016	USA
GW Pharma Limited	GREENWICH BIOSCIENCES	87/050601	26 May 2016	USA
GW Pharma Limited	GW Pharmaceuticals (stylised)	78/354188	20 Jan 2004	USA
GW Pharma Limited	SATIVEX	85/370291	13 Jul 2011	USA
GW Research Limited	CANNABIDEX	85/379901	25 Jul 2011	USA
GW Research Limited	CRI	87/771644	26 Jan 2018	USA
GW Research Limited	ALIGHT	88/730506	17 Dec 2019	USA
GW Research Limited	ASCELTA	86/938978	14 Mar 2016	USA
GW Research Limited	CANNABINOID RESEARCH INSTITUTE	87/771739	26 Jan 2018	USA
GW Research Limited	CEPADEX	85/959272	13 Jun 2013	USA
GW Research Limited	ENGAGE BY GREENWICH BIOSCIENCES Logo	88/226693	12 Dec 2018	USA
GW Research Limited	EPIDIOLEX	86/007888	11 Jul 2013	USA
GW Research Limited	EPINUKIA	86/938999	14 Mar 2016	USA
GW Research Limited	EPIVARIN	86/243559	05 Apr 2014	USA
GW Research Limited	EPIVARINEX	86/242714	04 Apr 2014	USA
GW Research Limited	KATEULIA	86/939170	14 Mar 2016	USA
GW Research Limited	KYNEUBIA	86/939158	14 Mar 2016	USA
GW Research Limited	KYTEUVIA	86/939190	14 Mar 2016	USA
GW Research Limited	CANNABIDEX	88/176634	31 Oct 2018	USA
GW Pharma Limited	SATIVEX	488647	23 Oct 2017	Uruguay
GW Pharma Limited	ASCELTA	506375	19 Jul 2019	Uruguay
GW Pharma Limited	SATIV	508710	04 Oct 2019	Uruguay
GW Pharma Limited	SATIV	2019-008635	04 Sep 2019	Venezuela
GW Pharma Limited	SATIVEX	002277-2010	17 Feb 2010	Venezuela
GW Pharma Limited	ASCELTA	2019-008014	18 Sep 2019	Venezuela

D. IP Agreements

Copyright Licenses:

None.

Patent Licenses:

Yissum Research Development Company of the Hebrew University of Jerusalem owned Patents exclusively licensed to GW Pharma Limited

Owner	Title	Application Number	Patent Number	Grant Date	Country
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	1476145	12/Feb/2014	Europe
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	1476145	12/Feb/2014	France
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	60345686	12/Feb/2014	Germany
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	04101860.1	HK1059214	03/Mar/2006	Hong Kong
Yissum Research Development Co of the Hebrew Univ of Jerusalem Limited	Use of cannabidiol compound in the manufacture of a non-psychoactive medicament	148244	148244	06/Jan/2008	Israel
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	50201490225974 9	12/Feb/2014	Italy
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	EP1476145	12/Feb/2014	Netherlands
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	03703002	12/Feb/2014	Spain
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	1476145	12/Feb/2014	Switzerland
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	0303604.3	GB2386322	23/Nov/2005	United Kingdom
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-nausea and anti-vomiting activity of cannabidiol compounds	03703002.0	EP1476145	12/Feb/2014	United Kingdom
Yissum Research Development Company of the Hebrew University of Jerusalem	Anti-Nausea and Anti-Vomiting Activity of Cannabidiol Compounds	11/454,703	8,119,697	21/Feb/2012	USA

Trademark Licenses:

None.

Commercial Tort Claims

None.

Schedule IV to
Supplement No. 1 to the
Collateral Agreement

Perfection Certificate

[See separate document.]